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Abstract 
 
The increased number of individuals with metabolic diseases has become a public 
health concern. Vitamin A (VA, retinol) is required to maintain the general health of an 
individual. How VA contributes to the regulation of glucose and lipid homeostasis in 
normal and metabolic disease states is unclear. VA’s physiological activities are mainly 
mediated by its metabolite, retinoic acid (RA), which activates several transcriptional 
factors in the nuclear receptor super family and in turn, regulates the expression of 
numerous genes for macronutrient metabolism. For the RA production, retinol is first 
oxidized into retinal and then from retinal to RA. We hypothesize that VA status and 
dynamic production of RA play a role in the control of glucose and fatty acid 
metabolism. This dissertation summarized my investigation of VA’s role in metabolism: 
(1) We compared the expression levels of RA-producing enzymes in the liver of Zucker 
lean (ZL) and fatty (ZF) rats. We found that the hepatic expression levels 
of retinaldehyde dehydrogenase family 1 gene (Raldh1) mRNA and RALDH1 protein 
were higher in ZF rats than that in ZL rats. This elevated RALDH1 expression may cause 
the excessive RA production, which may enhance the hepatic lipogenesis and lead to the 
hepatic insulin resistance;  (2) We compared the expression levels of insulin-regulated 
genes in the liver of VA deficient (VAD) and VA sufficient (VAS) ZL rats in response to 
the cycle of fasting and refeeding, a normal physiological condition. We observed that 
VA status and its dietary availability play a role in the expression levels of insulin-
regulated gene in the rat liver; (3) We further used streptozotocin (STZ) to induce insulin-
dependent diabetes mellitus in both VAD and VAS rats, a disease condition. The hepatic 
 vi 
expression levels of insulin-regulated genes in these animals treated with control, RA, 
insulin and insulin + RA were investigated. The effects of VA status and RA production 
on the regulation of the hepatic gene expression were also observed. We conclude that 
VA status and dynamic RA production contribute to the expression of hepatic genes, 
which in turn regulate glucose and fatty acid homeostasis. 
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Chapter One 
Introduction 
1. Vitamin A 
1.1. The Discovery of vitamin A  
The early studies of vitamin A (VA, retinol) activities can be dated back to 19th 
century. In 1881, Nicolai Ivanovich Lunin claimed that “a natural food such as milk must 
contain, besides the known principal ingredients (protein, sugar, fat, and salts), small 
quantities of other and unknown substances essential to life” [1]. In 1891, Carl A. Socin 
showed that an unknown fat-like substance in egg yolk was essential to life [2]. In 1906, 
Frederick Gowland Hopkins stated that “no animal can live upon a mixture of pure 
protein, fat, and carbohydrate, and even when the necessary inorganic material is 
carefully supplied the animal still cannot flourish” [3]. In 1909, Paul Knapp continued 
Lunin’s study on the substances of milk and observed that the animals fed a diet of 
protein, carbohydrate, fats, and minerals developed conjunctivitis and corneal ulceration 
prior to death, but the eye disease could be avoided if milk was provided [4]. In 1911, 
Wilhelm Stepp further indicated that “certain lipid substances present in milk and soluble 
in alcohol-ether are indispensable for the survival of mice” [5]. In 1914, following the 
previous investigations, Thomas Osborne and Lafayette Mendel reported that rats fed a 
basal diet developed inflamed eyes and diarrhea, which could be prevented when cod 
liver oil or butter fat was added to the diet, suggesting a lipid derived factor that is 
essential to life [6]. In 1918, Elmer McCollum suggested this “factor” that supported 
growth and eye health be named “fat-soluble A” in distinction to “water-soluble B” [7]. 
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In 1920, Jack Cecil Drummond named all the vitamins as “vitamin A, B, C, etc.” [8]. The 
chemical structure of β-carotene, precursor of VA, was described by Paul Karrer in 1931, 
which led to the clarification of the structure of retinol [9]. Ruth Corbet crystallized VA 
in 1937 [10]. Later, David Adriaan van Dorp and Jozef Ferdinand Arens synthesized VA 
[11] and Otto Isler developed a method for widespread production of VA [12]. The 
functions of VA were slowly disclosed through clinical observations including its 
important role in vision which was discovered by George Wald [13]. 
1.2. Sources, Digestion, and Absorption of VA 
1.2.1. Sources of VA 
Figure 1-1 shows molecules with VA activities. The nutritional need for retinol 
(Figure 1-1A) can be met by sufficient intake from the diet of these molecules. The 
dietary molecules with VA activities are in two forms, preformed VA (retinol and retinyl 
esters) and provitamin A (carotenoids).  
Preformed VA is found primarily in animal-derived food sources, especially the 
liver and dairy products including whole milk, cheese, and butter as well as fish [14]. The 
main preformed VA in these foods is as either retinol or retinyl esters, mainly retinyl 
palmitate (as shown in Figure 1-1B), which can undergo oxidation if exposed to varying 
degrees of oxygen, heat, and some metals [14]. Retinyl palmitate, the ester form of VA 
(retinol conjugated with palmitic acid) is frequently used as a cosmetic ingredient [15].  
Provitamin A carotenoids are abundant in many fruits and vegetables in the forms 
of β-carotene (Figure 1-1C), α-carotene (Figure1-1D), and β-cryptoxanthin (Figure 1-1E) 
[16]. Dietary β-carotene is present at high levels in carrots, and yellow and green leafy 
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vegetables; α-carotene is present in carrots and red palm oil; and β-cryptoxanthine is 
found in sweet red pepper, oranges, and papayas [16].  
 
     
                  (A) All-trans retinol                                    (B) Retinyl palmitate 
 
                                     (C) β-carotene 
 
                                     (D) α-carotene 
 
                                    (E) β-cryptoxanthin 
 
Figure 1- 1 Structure of representatives of molecules with VA activities.  
(A) All-trans retinol, (B) Retinyl palmitate, (C) β-carotene, (D) α-carotene, and (E) β-
cryptoxanthin. 
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1.2.2. Recommended dietary allowance of VA 
The international unit (IU) had been established and used to describe VA activity 
as the basis for Nutrition Labeling [17]. In 1989, the unit was replaced with retinol 
equivalents (RE) through which VA activity was expressed based on the equivalent 
weight of retinol [18]. Currently, the recommended dietary allowances (RDAs) for VA 
are recognized as micrograms (µg) of retinol activity equivalents (RAE) to account for 
the different bioactivities of retinol and carotenoids [19].  
1 IU = 0.3 µg retinol or 0.6 µg β-carotene or 1.2 µg other carotenoids; 
1 RE = 1 µg retinol or 6 µg β-carotene or 12 µg other carotenoids; 
1 RAE = 1 µg retinol or 12 µg β-carotene or 24 µg other carotenoids [20]. 
Current U.S. RDAs for VA are 900 µg RAE/day for adult men and 700 µg 
RAE/day for adult women [19]. 
1.2.3. Digestion and Absorption of VA 
Dietary molecules with VA activities are typically bound to other components in 
the food. They have to be digested to an absorbable form. In the diet from animal source, 
retinol is often esterified with fatty acids to form retinyl esters, mainly retinyl palmitate. 
The dietary retinyl esters and carotenoids are in complexes with proteins. In the stomach, 
the release of retinyl esters and carotenoids from protein complexes is initiated by the 
action of pepsin, which digests proteins. The released retinyl esters and carotenoids 
coalesce to form fat globules due to their fat solubility. These fat globules are then moved 
into the duodenum where proteolytic enzymes further hydrolyze proteins and release any 
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protein-bound retinyl esters or carotenoids. In the lumen of the small intestine, retinyl 
esters are hydrolyzed by retinyl ester hydrolases (REH) to retinol and the corresponding 
fatty acids. Hydrolysis of retinyl esters requires bile salts that solubilize the retinyl esters 
in micellar particles and activate the hydrolyzing enzymes. The different hydrolyzing 
enzymes have distinct substrate specificities: pancreatic esterase preferentially cleaves 
short-chain retinyl esters, whereas intestinal brush-border hydrolases prefers long-chain 
retinyl esters.  
The released free retinol and carotenoids, solubilized in micelles with other fat-
soluble food components, are then absorbed by the enterocytes. Most of the retinol is 
passively absorbed by the enterocytes with a relatively high efficiency (70%-90%). 
Carotenoids are absorbed into the enterocytes by passive diffusion with a low efficiency 
(9%-22%). Within enterocytes, cellular retinol-binding protein (CRBP) II binds to 
retinol, which is then esterified by lecithin:retinol acyltransferase (LRAT) with palmitic 
acyl CoA to form CRBP II-retinyl palmitate. The newly formed retinyl esters are packed 
in chylomicrons along with triacylglycerols, phospholipids, and cholesterol esters. 
Chylomicrons are transported to the lymphatic system and ultimately into the blood 
circulation. Chylomicrons deliver retinyl esters and unesterified retinol to extrahepatic 
tissues, and the retinyl esters not taken up by the tissues are transported to the liver as part 
of the chylomicron remnants. About 70%-75% of chylomicron retinoids are cleared from 
circulation by the liver.  
Within the enterocytes, β-carotene is either hydrolyzed by noncentral cleavage 
enzymes generating alcohol and aldehydes or by β-carotene 15,15’-oxygenase forming 
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retinal (one molecule of β-carotene forms two molecules of retinal) which is then 
primarily reduced to retinol and bound to CRBP II. About 60-70% of β-carotene is 
cleaved and the remainder is transferred into blood deposited in liver and adipose tissue. 
CRBP II-bound retinol is then esterified by LRAT and incorporated into chylomicrons. A 
small portion of retinal is oxidized to retinoic acid (RA), bound to albumin, and 
transported through the portal venous system [14, 16, 21, 22]. 
1.3. Storage of VA 
The liver is the major organ for VA storage. Some retinyl esters are stored in the 
parenchymal cells, but almost 80%-95% of retinyl esters are stored in stellate cells [14]. 
In the parenchymal cells, retinol and fatty acids are released from retinyl esters. Free 
retinol and CRBP-bound retinol are esterified via acyl-CoA:retinol acyltransferase 
(ARAT) and LRAT to form retinyl esters. Retinyl esters are stored with lipid droplets in 
the stellate cells until needed. Hydrolases can release the retinol from the stores to 
maintain retinol homeostasis [14]. VA is transported between the parechymal and stellate 
cells in the form of free retinol though the mechanism is not completely understood.  
1.4. Cellular Metabolism of Retinol 
1.4.1. Cellular Retinol Binding Proteins 
Due to the hydrophobic nature, free retinoids are mainly associated with proteins. 
Within the cells, retinol binds with CRBP, and RA binds with cellular retinoic acid 
binding protein (CRABP) [14]. Most tissues contain CRBPs, especially the liver, kidney, 
intestine, and male reproductive organs. Some of these tissues and the skin also contains 
CRABPs [23]. CRBP and CRABP are thought to function as “buffer proteins” to control 
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the concentrations of free or unbound retinol and RA within the cells, and as “guide 
proteins” to direct retinoids to specific enzymes of metabolism to prevent nonspecific 
oxidation [23]. Unbound CRBPs are also thought to inhibit LRAT and thereby prevent 
esterification of retinol for storage [14].  
To date, three CRBP isoforms (CRBP I, II, and III) have been identified [24]. The 
roles of CRBP I and CRBP III are to facilitate the esterification of retinol to retinyl ester 
catalyzed by LRAT [25, 26]. Both CRBP I and CRBP III are expressed in adipose tissues 
with CRBP I in preadipocytes and CRBP III in adipocytes, and they are reported to play 
important roles in adipogenesis [27]. Lack of CRBP I led to increased adiposity [28], 
whereas mice lacking CRBP III developed decreased adiposity [29]. It seems that CRBP 
I and III play opposit roles in adipogenesis with CRBP I repressing and CRBP III 
maintaining adipogenesis. 
1.4.2. The conversion of retinol to retinal 
Within the liver, both hepatocytes and hepatic stellate cells are involved in 
retinoid metabolism. In hepatocytes, retinyl esters are hydrolyzed to retinol, which is then 
either oxidized to RA through a two-step reaction, or bound to retinol binding protein 
(RBP) and secreted out into circulation for the uptake of extrahepatic target tissues 
including adipose tissue [14]. In hepatic stellate cells, retinol is re-esterified to retinyl 
ester by LRAT and stored there [30]. The first step of retinol oxidation, from retinol to 
retinal (also called retinaldehyde), is reversible and is catalyzed by retinol 
dehydrogenases (RDHs), which belong to the cytosolic alcohol dehydrogenases (ADHs) 
of the medium-chain dehydrogenase/reductase (MDR) superfamily and microsomal 
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retinol dehydrogenases of the short-chain dehydrogenase/reductase (SDR) superfamily 
[31] (Figure 1-2).  
Four classes of ADH, ADH1-4, exist in both mice and humans with all genes in 
both species localized in a single tandem cluster in the same order and same 
transcriptional orientation [32]. ADH4 is expressed at high levels in the stomach and 
esophagus but is totally absent from the liver, whereas ADH1, ADH2, and ADH3 are 
highly expressed in the liver [32]. The knockout studies demonstrate that ADH1, ADH3, 
and ADH4 function in retinol metabolism [33-35]. ADH1 functions as the primary 
enzyme responsible for the efficient oxidative clearance of excess retinol, providing 
protection and increased survival during VA toxicity [35]. ADH4 functions in 
metabolism of retinol to retinal in peripheral tissues to provide protection against VA 
deficiency [36]. ADH3 alone is adequate to catalyze the oxidation of retinol to retinal 
under VA sufficiency, but ADH4 overlaps its function during VA deficiency and ADH1 
overlaps its function during VA toxicity [34].  
At least three RDHs (RDH1, RDH2 and RDH10) are thought to be involved in 
the first step of RA biosynthesis. RDH1 and RDH2 recognize CRBP-bound retinol as 
substrate, and have higher activity with NADP than NAD as a cofactor [37, 38]. RDH1 
has higher activity toward to all-trans retinol than to other cis-retinols, and its function in 
retinal biosynthesis starts early during embryogenesis [39]. RDH2, identified as protein 
p29 in another study [40], is thought to have retinal reductase activity in the presence of 
NADPH and the addition of proteins CYP2D1. NADPH-P450 increased RDH2 reductase 
activity, contributing to retinoid metabolism [41]. RDH3 is only expressed in the liver. It 
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has 97.8% identity with RDH1 and 82.3% identity with RDH2 [42]. RDH10 was first 
cloned in the retinal pigment epithelium [43] and then in retinal Muller cells [44]. 
RDH10 is correlated with several sites of all-trans RA biosynthesis in the mouse 
embryos [45, 46]. Both RDH1 and RDH10 are active with oxidation of all-trans retinol 
and 9-cis retinol [47].  
1.4.3. The conversion of retinal to retinoic acids  
The second step of RA production is retinal oxidation, from retinal to RA. It is 
catalyzed by cytosolic aldehyde dehydrogenases (ALDHs) [31]. To date, four RALDHs 
(ALDHs), RALDH1 (or ALDH1A1), RALDH2 (or ALDH1A2), RALDH3 (or 
ALDH1A3), and RALDH4 (or ALDH8A1), have been cloned in rats and believed to be 
responsible for all-trans RA or 9-cis RA production in various tissues (Table 1-1) [48-
51].  
The 2.3 kb mRNA of RALDH1 is highly expressed in the embryonic and adult 
dorsal retina as well as in the liver of adult mice [52]. RALDH1 accounts for at least 90% 
of the all-trans and 9-cis retinal dehydrogenase activities in adult rat/mouse liver and 
kidney while RALDH2, -3, and -4 contribute to the remaining activity without apparent 
domination by any one [51].  
Overexpression of mouse RALDH1 in Xenopus embryo leads to premature 
synthesis of RA during embryogenesis, indicating its involvement in RA biosynthesis 
[53]. Elevated RA was thought to control its own production through the feedback 
inhibition of RALDH1 expression via retinoic acid receptor α (RARα) by decreasing the 
C/EBPβ (CCAAT/enhancer binding protein β) concentration [54]. The mechanism was 
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later confirmed as that all-trans RA increases the GADD153 and C/EBPβ interaction 
[55]. RALDH1 has been associated with obesity and energy balance [56]. RALDH1 
expression was up-regulated in the kidney and liver of db/db mice with decreased levels 
of all-trans RA which may cause the compensatory increase in RALDH1 [57]. The 
Raldh1-/- mice are protected against diet-induced obesity (DIO) and insulin resistance 
[56]. Deficiency of Raldh1 gene activates a brown adipose tissue (BAT)-like thermogenic 
program in white adipose tissue (WAT), promoting energy dissipation [58]. Raldh1-
deficient mice also display decreased gluconeogenesis and attenuated hepatic 
triacylglycerol synthesis [59]. The mechanism has been thought that RALDH1 generates 
the major amount of all-trans RA used to promote adipogenesis and RALDH1 deficiency 
impairs all-trans RA production, therefore decreasing adipogenesis, specifically in 
visceral fat. Thus, the inhibition of RALDH1 activity may influence depot-specific fat 
formation [60]. 
The amino acid sequence of RALDH2 has the highest identity (71.5%) and 
similarity with RALDH1 [61]. The Raldh2-/- embryos can be rescued with external 
administration of RA, which leads to the conclusion that RA synthesized by RALDH2 is 
required for early embryonic development [62]. Overexpression of mouse RALDH2 in 
Xenopus embryos resulted in high levels of RA, suggesting its distinct role in retinoid 
signaling pathway by elevating RA biosynthesis [63]. The analysis of RALDH2 promoter 
indicated the presence of binding site for sterol regulatory element binding proteins 
(SREBPs) [64]. Cholesterol metabolite, oxysterol, was demonstrated to induce RALDH1 
and RALDH2 expression through the activation of SREBP-1c and liver X receptor α/β 
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(LXRα/β), establishing the crosstalk between cholesterol metabolism and all-trans RA 
biosynthesis [65].  
Mouse RALDH3 shares 70% sequence identity with RALDH1 and 71% sequence 
identity with RLAHD2 [66]. RALDH3 oxidizes all-trans retinal but does not show 
activity for either 9-cis or 13-cis retinal substrates [67]. RALDH3 expression in embryos 
is distinct from that of RALDH1 or RALDH2, showing its unique role in organ 
development [66]. The Raldh3-/- mutants have defects in nasal and ocular development, 
demonstrating its importance in nasal development [68]. Overexpression of RALDH3 
reduced insulin secretion but increased glucagon secretion in vitro, indicating that 
RALDH3 disrupts the balance between insulin and glucagon, and may induce β-cell 
dysfunction leading to the development of type 2 diabetes mellitus (T2DM) [69]. 
RALDH4 is inactive for all-trans retinal but exhibits high activity for 9-cis retinal 
oxidation [67]. RALDH4 functions with cis-retinoid/androgen dehydrogenase 1 
(CRAD1), CRAD3, or RDH1 to generate 9-cis RA, and has a unique expression pattern 
in kidney compared with three other ALDHs [51]. 
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Figure 1- 2 VA metabolism and RA signaling.  
Retinyl esters are hydrolyzed to retinol and free fatty acids after they enter hepatocytes. 
Retinol is reversibly oxidized to retinal by RDHs. RDH1, 2, and 10 are the major 
enzymes in the conversion from retinol to retinal. RDH2 has reductase activity, which is 
able to reduce retinal back to retinol. Retinal can be irreversibly oxidized by RALDHs 
(RALDH1 to 4) to RA. RALDH1 is the major enzymes catalyze the conversion from 
retinal to RA. RA can be modified to more hydrophilic metabolites by CYP26, especially 
CYP26A1. RA is the active form of VA functioning in the regulation of nuclear gene 
expression by binding to nuclear receptors mediating RA effects. In the presence of RA, 
heterodimer RAR/RXR or other nuclear receptors associated with RARE recruit co-
factors to modulate target gene expression. 
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Table 1- 1 Enzymes in RA biosynthesis 
Name Substrates Major expression sites Km 
Alcohol dehydrogenases (ADH) / Retinol dehydrogenases (RDH) 
ADH1  Liver, kidney  
ADH3  Ubiquitous  
ADH4  Stomach  
RDH1 
Oxidation: all-trans retinol, 9-cis 
retinol 
Liver, kidney, lung, testis, 
brain 
0.9 µM 
RDH2 
Reduction & oxidation: all-trans-
retinol 
Liver, kidney, lung, testis, 
brain 
2 mM 
RDH10 
Oxidation: all-trans retinol, 9-cis 
retinol 
Retina  
Aldehyde dehydrogenases (ALDHs) 
RALDH1 
Oxidation: all-trans retinal, 9-cis 
retinal 
Liver, kidney, small 
intestine,  
pituitary glands 
1.4 µM 
RALDH2 
Oxidation: all-trans retinal, 9-cis 
retinal 
Liver, kidney, small 
intestine,  
testis, pituitary glands, lung, 
heart 
0.2 µM 
RALDH3 Oxidation: all-trans retinal Kidney, pituitary glands 0.2 µM 
RALDH4 Oxidation: 9-cis retinal Liver, kidney  
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1.4.4. The further catabolism of RA, studies of CYP26A1 
Cytochrome P450 family 26 (CYP26) enzymes have been identified as a major 
contributor to the oxidative metabolism of RA in various tissues [70]. Oxidation of RA 
by CYP26 goes through two phases, oxidation and conjugation. During phase 1, RA is 
oxidized by CYP26 to polar metabolites, 4-hydroxy-RA and 4-oxo-RA. They are then 
converted by uridine 5’-diphospho-glucuronosyl transferases to water-soluble compound, 
4-O-β-glucuronide [70]. The CYP26 family includes CYP26A1, CYP26B1, and 
CYP26C1, and they eliminate RA in different tissue-specific patterns [70]. CYP26A1 
was first discovered in zebrafish as P450RAI [71], and then the cDNA of CYP26A1 was 
cloned in human and several other species [72]. It has been shown that all-trans RA is not 
only the substrate of CYP26A1 but also a potent inducer of it, which is particularly 
evident in the liver [73]. CYP26A1 is the most sensitive liver-expressed gene in response 
to the dietary VA intake and exogenous RA treatment [74]. It has been widely accepted 
that CYP26A1 is the primary enzyme that mediate clearance of endogenous RA [75]. 
Hepatocytes sense the concentration of RA effectively upon RA entering into the cells, 
which triggers CYP26A1 and UDP-glucuronidyl transferases to convert excess RA to 
water-soluble compounds for their elimination from the body as biliary metabolites [70]. 
Thus, CYP26A1 is usually considered as an indicator of RA production due to its 
sensitivity to the increase in cellular RA concentration [76]. 
Some studies have reported an increase in CYP26A1 mRNA expression in cancer 
cells and tumors [77-79], suggesting a link between CYP26A1 and tumorigenicity. 
Therefore, suppression of the catalytic activity of CYP26A1 has been brought up as a 
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therapeutic approach for the treatment of some types of cancer, like leukemia. A number 
of RA metabolism-blocking agents (RAMBAs) have been developed to inhibit all-trans 
RA metabolism by CYP26A1 [80].    
1.5. Isomers of retinoic acids 
The molecules with part or all of VA activities share a 20-carbon structure with a 
methyl substituted cyclohexenyl ring and a tetraene side chain with a hydroxyl group 
(retinol), aldehyde group (retinal), carboxylic acid group (retinoic acid), or ester group 
(retinyl ester) at carbon-15 [19]. The all-trans and three mono-cis isomers, 9-cis, 11-cis, 
and 13-cis, have been reported to play specific physiological role in nature [81]. 
RA derivatives have been used in the treatment of a lot of diseases over a long 
time. As shown in Table 1-2, RA isomers include isotretinoin (13-cis RA), tretinoin (all-
trans RA), acitretin, bexarotene and alitretinoin (9-cis RA) [82]. They have different 
stereo structures and regulate target gene expression through activating specific nuclear 
receptors, RAR or retinoid X receptor (RXR) [82]. Isotretinoin (13-cis RA), tretinoin (all-
trans RA), and acitretin (9-cis RA) primarily bind to RAR. Bexarotene (9-cis RA) binds 
to RXR in T-cell lymphoma, and alitretinoin (9-cis RA) binds to both RAR and RXR in 
skin cells [82]. 
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Table 1- 2 Profiles of RA derivatives  
Name Receptors Treatment 
Tretinoin RAR 
Acute promyelocytic 
leukemia 
Isotretinoin RAR Acne 
Acitretin RAR Psoriasis, lichen planus 
Bexarotene RXR Cutaneous T-cell lymphoma 
Alitretinoin RAR/RXR Chronic hand dermatitis 
 
 
1.6. Retinol transport and distribution 
1.6.1. Transport of retinol from the liver to other tissues 
VA is transported in the blood in the form of retinol, bound to a specific protein, 
RBP which is synthesized by hepatic parenchymal cells. Synthesis of RBP depends on 
the protein, retinol, and zinc status of the body [14]. RBP was first isolated in 1968 by 
Masamitsu Kanai et al. [83], and its structure and physical properties have been well 
studied. RBP is a single polypeptide chain with a molecular weight of approximately 21 
kDa, and has a single binding site for one molecule of all-trans-retinol [84]. In 
hepatocytes, retinol combines with RBP to form the retinol-RBP complex, holo-RBP, 
which is then released to the blood [85]. In the blood circulation, RBP interacts with 
another protein, transthyretin (TTR), a tetrametic protein with two identical thyroxine-
binding sites, to form holo-RBP-TTR complex which is then bound to thyroxine (T4) to 
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form a trimolecular complex. [14]. The normal level of RBP in plasma is about 40-50 
µg/ml, and that of TTR is about 200-300 µg/ml [86]. Retinol mobilization and delivery 
are regulated by the processes that control the rates of RBP synthesis and secretion by the 
liver [85]. Specific cell surface receptors that recognize RBP may be involved in the 
delivery of retinol to peripheral tissues [87-89]. STRA6, a multitransmembrane domain 
protein, was reported by Riki Kawaguchi et al. as a specific membrane receptor for RBP 
[90]. However, other view supports that the uptake of retinol from RBP is receptor 
independent [91, 92]. 
1.6.2. RBP4 and its role in insulin resistance 
RBP4 is recently identified as an adipokine that is linked to adiposity, insulin 
resistance, and T2DM. Barbara Kahn’s research group found that mice with an adipose-
specific knockout of glucose transporter type 4 (GLUT4), a glucose transporter that 
mediates insulin-stimulated glucose uptake in adipocytes and muscle, developed insulin 
resistance in the muscle and liver, suggesting that a circulating factor secreted from the 
adipocytes that causes the observed changes [93]. They then indicated that RBP4 may be 
the circulating factor and showed that expression of RBP4 was elevated in adipose tissue 
of adipose-Glut4 -/- mice. They also showed that serum RBP4 levels were elevated in 
insulin-resistant mice and human subjects with obesity and T2DM. Transgenic 
overexpression of human RBP4 or injection of a recombinant RBP4 in normal mice 
caused insulin resistance, whereas genetic deletion of Rbp4 enhanced insulin sensitivity. 
Moreover, administration of fenretinide, a synthetic retinoid, normalized serum RBP4 
levels of obese mice [94]. These studies demonstrate that RBP4 overexpression may 
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affect insulin sensitivity and contribute to T2DM. The absence of RBP4 may improve 
insulin sensitivity.  
In clinical studies, the causality of increased serum RBP4 levels and insulin 
resistance is controversial. In some studies, serum RBP4 levels were reported to be 
higher in subjects with impaired glucose tolerance, T2DM, and to be correlated inversely 
with insulin sensitivity in non-diabetic subjects with family diabetes history [95, 96]. The 
improvement of insulin resistance after exercise training is associated with reduced serum 
RBP4 levels [95]. Significant weight loss after bariatric surgery resulted in decrease of 
circulating RBP4 levels [97]. All these results indicate that lowing circulating RBP4 
levels is a potential treatment strategy to increase insulin sensitivity and improve T2DM. 
RBP4 seems to be an adipokine that is involved in the early phases of the development of 
insulin resistance and other components of the metabolic syndrome [98]. 
However, in other studies, such association was not observed in either healthy 
[99] or obese subjects [100, 101]. RBP4 gene expression in nondiabetic human subjects 
was not related to insulin resistance [102].  
The molecular mechanism of serum RBP4 effects on insulin sensitivity has not 
been completely understood. Qin Yang et al. claimed that increased release of RBP4 
from adipocytes interrupts insulin signaling in the muscle by reducing phosphoinositide-
3-kinase (PI-3-kinase) activity and subsequent phosphorylation of insulin receptor 
substrate-1 (IRS-1), and increased the expression of enzyme phosphoenolpyruvate kinase 
(PEPCK) in liver, resulting in increased hepatic glucose output [94]. The link between 
RBP4 and T2DM may also be mediated through the negative effects of RBP4 on β-cell 
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function through preventing the binding of TTR to its receptor [101]. Several RBP4 
single nucleotide polymorphisms (SNPs) and their haplotypes are likely to affect 
measures of insulin resistance and RBP4 mRNA levels in visceral adipose tissue in 
humans, which may result in T2DM [103].  
The fact that RBP4 is a transport protein for retinol increases the possibility that 
alteration of retinol metabolism might influence the action of insulin. Thus, it is of 
importance to determine the effects of dietary VA intake on insulin sensitivity and 
plasma RBP4 levels. 
1.7. Functions of VA 
VA and its metabolites play roles in a spectrum of biological functions, including 
vision, immunity, cellular differentiation, and signaling.  
1.7.1. Roles of VA in vision 
Night blindness has been known since ancient Egyptian times and eating raw liver 
was recognized as a cure for night blindness [104]. In early 1900s, cod liver oil was 
discovered as a cure for night blindness and the symptom could be reversed by a diet 
including whole milk or butter in which the essential nutritional factor was later 
discovered as “fat-soluble VA” by Thomas Osborne and Lafayette Mendel [104]. 
A number of studies have demonstrated the link between VA and night blindness. 
VA is important in the visual cycle, which depends on the roles of 11-cis-retinal in the 
transduction of light into neural signals necessary for vision [105], and RA in maintaining 
normal differentiation of the cornea and conjunctival membranes [106]. Photons enter the 
eye through the cornea, then pass through the lens and the vitreous humor, and hit the 
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retina. The photoreceptors of the retina consist of rods, which are stimulated by weak 
light of a broad range of wavelengths, and cones, which are responsible for color vision 
under bright light. Retinal is essential to form rhodopsin, a retinal-containing pigment 
protein that is made up of cis-retinal and opsin in the rod. In the rod visual cycle, 
absorption of a photon by rhodopsin-bound 11-cis-retinal causes isomerization of 11-cis-
retinal to form all-trans-retinal, and releases opsin, producing the visual signal that is sent 
to the brain. To regenerate rhodopsin again, released all-trans-retinal is reduced to all-
trans-retinol and transported from the rods into the pigment epithelium of the retina, 
where it is catalyzed by LRAT to all-trans-retinyl esters. All-trans-retinyl esters are then 
converted to 11-cis-retinol, which is attached to cellular retinal-binding protein 
(CRALBP). This compound is oxidized to 11-cis-retinal, which detaches from CRALBP 
and transports back to rods and reattached to opsin to form rhodopsin, a process closing 
the visual cycle. Inadequate VA supply may result in failure or delayed recovery of 
vision in the dark, which results in night blindness [14, 21, 107, 108]. 
1.7.2. Roles of VA in immunity 
VA also plays an important role in enhancing immune responses. RA stimulates 
phagocytic activity and cytokine production, and maintains natural killer cell 
concentrations. VA is also needed for T-lymphocyte function and for antibody response 
to viral, parasitic, and bacterial infections [109]. Therefore, people with VA deficiency 
have reduced ability of regeneration of mucosal barriers damaged by infection, impaired 
protective functions of neutrophils, macrophages, and natural killer cells, diminished 
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antibody responses to antigens that require T-helper type 2 (Th2)-mediated help, which 
contribute to the greater risk of infection and increased severity of disease [109].  
1.7.3. Roles of VA in differentiation 
Many cells need VA, especially RA, for cell differentiation. For example, RA 
maintains the normal structure and function of the epithelial cells that are part of our skin 
and all internal body tracts. The mechanism is that RA is one of the signals that switch on 
the expression levels of genes for keratin proteins, thereby directs the differentiation of 
immature skin cells into mature epidermal cells [23]. 
Additionally, VA is required for bone health through involvement with 
osteoblasts (bone-forming cells) and osteoclasts (bone resorption cells). VA deficiency 
can cause excessive deposition of bone by osteoblasts and reduced bone degradation by 
osteoclasts [14]. 
1.7.4. The toxicity of excess VA intake 
The daily tolerable upper intake level (UL) for preformed VA for adults is 3,000 
µg RAE (10,000 IU) per day [19]. Acute VA toxicity has been reported to occur 
following consumption of polar bear and seal liver by Eskinos and Arctic explorers [21]. 
Excess VA intake in a short time can result in acute hypervitaminosis A with the 
symptoms of nausea, vomiting, double vision, headache, dizziness, and general 
desquamation of the skin. Chronic VA toxicity occurs following routine intake of large 
doses of VA over a period of several months, and is manifested by a variety of 
symptoms, including anorexia, desquamating skin, hair loss, headache bone and muscle 
pain, increased bone fractures, and liver damage [14]. Excess oral intake of VA also 
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causes birth defects. Use of Accurane, an acne treatment medicine containing 13-cis-RA, 
in the early months of pregnancy resulted in a number of birth defects among the infants 
[14]. One mechanism is that excess VA intake rises serum retinol levels, and retinol is no 
longer transported by RBP but is presented to the cell membranes, releasing toxic 
products [14]. 
1.8. Regulation of gene expression 
1.8.1. The nuclear receptor super family and their activation mechanism 
Nuclear receptors are a family of ligand-activated transcription factors that play 
important roles in numerous physiological processes responding to lipophilic hormones, 
vitamins, dietary lipids, or other intracellular signals [110]. The nuclear receptors can be 
classified into three groups based on the understanding of the working mechanisms. The 
first group includes endocrine receptors with high affinity for fat-soluble hormones and 
vitamins, like RAR. The second group is named adopted orphans as their physiological 
ligands were not known when their cDNAs were identified based on sequence homology 
to endocrine receptors, like RXR, LXR, peroxisome proliferator-activated receptor 
(PPAR), and hepatocyte nuclear factor 4 α (HNF4α). The third group is named true 
orphans as the ligands or agonists for their activation are currently unknown [110].  
RA regulates gene expression through activation of two families of nuclear 
receptors, RAR activated by all-trans and 9-cis RA and RXR activated by 9-cis RA 
[111]. Each of them has three isoforms, α, β, and γ that are encoded by distinct genes. 
Each isoform has multiple subtypes produced by alternative splicing or differential 
promoter use. RAR/RXR hetero- or RXR/RXR homo-dimer binds to the RA responsive 
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elements (RARE) at the promoters of their downstream targeted genes and recruits 
cofactors to regulate transcription of these genes in the presence of retinoids.  
1.8.2. Retinoic acid receptors 
Three isoforms of RAR, α, β, and γ, were first identified in 1987 independently by 
Chambon’s and Evans’s groups [112, 113] and they originate from three distinct genes 
[114]. RARs can bind to RXRs to form heterodimers and then bind to the specific RARE 
sequences located at the promoter region of the target genes. In the absence of RAR 
agonist, the RAR/RXR heterodimer recruits co-repressor proteins to prevent 
transcription; when RAR agonist binds to it, co-repressors are released and co-activator 
proteins are recruited to activate transcription [115, 116]. However, RXR agonists are 
unable to activate the heterodimer without RAR ligand [117]. 
The link between all-trans RA and acute promyelocytic leukemia (APL) had been 
established by Hugues de Thé [118], who found that a translocation occurred in APL 
cells in which RARα gene is fused to the promyelocytic leukemia (PML) gene, producing 
a fusion protein PML/RARα. Expression of this protein led to the development of APL in 
transgenic mice harboring PML/ RARα gene in myeloid cells [119]. Normally, PML acts 
as a tumor suppressor protein but its function is blocked by the PML/ RARα fusion 
protein [120]. Later, all-trans RA was found to down-regulate RARα in a dose- and time-
dependent manner [121] and all-trans RA stimulates catabolism of the PML/RARα 
fusion protein, turning off its function [122]. 
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1.8.3. Retinoid X receptors 
RXR has three isoforms, RXRα, β, and γ that are encoded by three distinct genes 
[123]. 9-cis RA is a high-affinity ligand for all three RXR isoforms [123]. RXRs can 
function as a homodimer (RXR/RXR) or heterodimers with other nuclear receptors, such 
as RAR, PPAR, LXR, vitamin D3 receptor (VDR), or thyroid hormone receptor (TR) 
[21]. PPAR and LXR are permissive partners that can be activated by agonists of both 
RXR and the partner receptor independently or together; RAR, TR, and VDR are non-
permissive partners that cannot be activated by the agonist of RXR but only by the 
agonist of the partner receptor [124]. 
PPARγ plays a major role in the regulation of glucose and lipid metabolism, and 
the rexinoid LG100754 efficiently induces lower glucose levels in rats with T2DM [125, 
126]. 
1.8.4. Other nuclear receptors 
Other than RARs and RXRs, many nuclear receptors mediate RA responses, such 
as HNF4α and chicken ovalbumin upstream promoter-transcription factors (COUP-TFs) 
[127].  
 
2. Metabolic diseases 
2.1. Obesity 
 For adults, overweight and obesity ranges are determined by using an 
individual’s weight in kilograms over height squared in meters to calculate body mass 
index (BMI). An adult who has a BMI between 25 and 29.9 is considered overweight. An 
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adult who has a BMI of 30 or higher is considered obese [128]. A child’s weight status is 
determined using an age- and sex-specific percentile for BMI rather than the BMI 
categories used for adults. Overweight is defined as a BMI at or above the 85th percentile 
and lower than the 95th percentile while obesity is defined as a BMI at or above the 95th 
percentile for children of the same age and sex [129]. 
In 2010, an estimated two-thirds (67%) of U.S. adults were overweight, and more 
than one-third (35.7%) of adults and almost 17% of youth were obese [130]. Non-
Hispanic blacks have the highest obesity rate (49.5%) compared with Mexican 
Americans (40.4%), all Hispanics (39.1%) and non-Hispanic whites (34.3%) [131]. 
Women with higher incomes or education levels are less likely to be obese than those of 
lower socioeconomic status (SES), whereas there is no significant association between 
obesity and SES among men [132]. Between 1960 and 1980, the obesity rate was 
relatively stable. But obesity rates for adults have doubled and rates for children have 
tripled regardless of sex, ethnicity, socioeconomic status, or geographic region since 1980 
[133]. The rate of obesity is increasing around the world according to the data from the 
World Health Organization (WHO) [134]. In 2010, 35.7% of U.S. adults were obese and 
almost 17% of youth were obese [130]. The latest analysis of National Health and 
Nutrition Examination Survey (NHANES) from 2009-2010 data suggested a slowing or 
leveling off of the prevalence of adult obesity in U.S. [131]. However, the prevalence 
remains unacceptably high and obesity continues to be a serious national health concern 
[133].  
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The development of obesity results in heath and economic consequences. 
Overweight and obesity increase the risk of many life-threatening diseases, such as 
T2DM, heart disease, hypertension, respiratory problems, osteoarthritis, gallbladder 
disease, and certain types of cancer [133]. It is reported that overweight and obesity are 
linked to more deaths worldwide than underweight. 65% of the world’s population live in 
countries where overweight and obesity kills more people than underweight [134]. 
Additionally, overweight and obesity decrease the quality of life due to limited physical 
mobility, incidence of discrimination, low self-esteem, and depression [133]. The annual 
medical burden of obesity and health-related problems has risen to almost 10% of all 
medical spending in U.S. [135]. 
2.1.1. Causes of obesity 
Obesity is fundamentally caused by an imbalance between food 
consumption/energy intake and physical activity/energy expenditure. When energy intake 
is greater than energy expenditure, energy balance is positive, which leads to weight gain 
and increased fat stores. On the other hand, when energy consumption is less than energy 
expenditure, energy balance is negative, which results in reduced body fat stores. Both 
environmental and genetic factors contribute to the development of overweight and 
obesity. The environmental factors such as consumption of sugar-sweetened beverages, 
increased portion size, decrease in physical activity, etc, have been proposed to play a 
role in the obesity development. Nearly half of the added sugar in the U.S. diet is from 
sugar-sweetened beverages, including carbonated drinks, sweetened fruit drinks, and 
sports beverages [136]. A lot of studies have shown that consumption of sweetened 
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beverages, especially those with high-fructose corn syrup, is associated with increased 
energy intake and incidence of obesity [137, 138].  
Genetic mutations also contribute to the development of obesity. For example, 
mutations of leptin gene and its receptor have been shown to cause the development of 
overweight and obesity [139]. The genes encoding leptin (Ob) and its receptors (Obr) 
were cloned in 1990s. The obese mice bearing a mutation of Ob gene is leptin deficiency 
[133]. Leptin, mainly from adipose tissues, is a circulating signal for the regulation of 
body weight and whole body energy expenditure [140]. Circulating leptin levels are 
correlated with the body fat [141] and the fasting and re-feeding cycle. The plasma leptin 
level falls markedly after fasting and rises promptly following the restoration of food 
intake [142]. When fat stores in adipocytes increase, more leptin is released as a signal to 
leptin receptors in the brain, resulting in a feeling of satiety and reduced food intake; 
when body fat stores decrease, lowered leptin levels lead to increase in food intake [143]. 
However, leptin deficiency is very rare in humans [144] and obese people who were 
given high doses of leptin only lost a small amount of weight [133]. Thus, human obesity 
is considered a leptin resistance state due to the elevated plasma leptin levels and reduced 
responses to the exogenous leptin treatment [145]. Leptin resistance could contribute to 
insulin resistance and the metabolic syndrome in human obesity [145]. 
2.1.2. Treatment of obesity 
A combination of lifestyle, behavioral, and dietary changes is required to lose 
weight due to the complexity of weight control. Individuals should match the calories 
consumed with energy expended to maintain a healthy body weight. The general energy 
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requirements range from 1,600 to 2,400 calories per day for adult women and 2,000 to 
3,000 calories per day for adult men [133]. In addition to calorie control and regular 
exercise, antiobesity drugs will enhance the effects of weight loss. Currently, 
sympathomimetic drugs and lipase inhibitors are the only two types of obesity 
medications that are approved by FDA [133]. Sympathomimetic drugs include 
Diethylpropion (Tenuate), Phendimetrazine (Bontril, Plegine), and Benzhetamine 
(Didrex) and they are only approved for short-term use (12 weeks) [133]. Orlistat 
(Xenical), a lipase inhibitor, is the only weight-loss medication that can be used for a 
long-term treatment [133]. It can inhibit the absorption for up to 30% of dietary fat at the 
recommended dose [133]. 
For people with severe obesity and chronic health conditions, bariatric surgery is 
the only intervention to induce significant weight loss [146]. Most bariatric surgery 
patients have experienced a number of attempts to lose weight by using nonsurgical 
methods [147]. Bariatric surgery procedures are categorized as malabsorptive, restrictive, 
and a combination of the two. Malabsorptive procedures reduce the food digestion and 
nutrient absorption of the stomach and the small intestine, which results in malabsorption 
[133]. 
2.2. Diabetes 
2.2.1. Definition of diabetes mellitus 
Until 2010, diabetes affects 25.8 million people, 8.3% of the U.S. population, 
including both diagnosed and undiagnosed people [148]. Both prevalence and incidence 
of diabetes are still increasing. Diabetes mellitus (DM) is characterized by abnormally 
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high levels of glucose in the blood due to deficiency of insulin secretion, or the resistance 
of the cells to the action of insulin, or to a combination of both [149]. The National 
Diabetes Data Group (NDDG) and the WHO classification system distinguishes four 
forms of DM, insulin-dependent DM/type 1 DM (T1DM), non-insulin-dependent 
DM/T2DM, other types of DM, and gestational DM [149].  
T1DM, formerly termed juvenile-onset DM, is mostly common among children 
and adolescents. T1DM is the result of β-cell destruction that leads to total loss of insulin 
secretion [149]. Patients with T1DM are dependent on exogenous insulin to sustain life. 
T2DM results from insulin resistance in the muscle, liver, and adipose tissue and 
eventually defects in insulin secretion. T2DM is typically unrecognized for years because 
of the lack of symptoms [149]. The causes of other types of DM include pancreatic 
disease, insulin receptor abnormalities, and pancreatic injury from drugs or chemicals 
[149]. Gestational DM is characterized by hyperglycemia that occurs in pregnancy [149]. 
The diagnostic criteria for DM are shown in Table 1-3. 
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Table 1- 3 Diagnostic criteria for DM 
Diabetes 
Symptoms of diabetes and casual plasma glucose ≥ 200 mg/dL 
Fasting plasma glucose ≥ 126 mg/dL 
Plasma glucose ≥ 200 mg/dL at 2 hr after a 75-g oral glucose challenge 
Pre-diabetes 
Fasting plasma glucose 110-126 mg/dL 
Normal  
Fasting plasma glucose < 110 mg/dL 
 
 
2.2.2. The link of obesity and T2DM 
T2DM accounts for approximately 90% of cases in the DM syndrome. Both 
genetic factors and environmental factors contribute to the development of T2DM. More 
than 80% of patients with T2DM are obese, but only 10% of obese subjects are diabetic. 
Increased food intake and decreased fat oxidation cause accumulation of TG in adipose 
tissues and the development of obesity. The TG storage capacity of fat cells becomes 
limited due to excessive accumulation of TG in them. This leads to an increase in plasma 
levels of TG and free fatty acid (FFA). Elevated plasma lipid levels lead to an increase of 
FFAs in liver and muscle cells, which inhibits the action of insulin in the skeletal muscle 
and liver, and causes insulin resistance and hyperinsulinemia. Impaired β-cell function is 
unable to compensate for insulin resistance, causing onset of T2DM [149]. Insulin 
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secretion eventually declines in obese subjects due to genetic reasons, which results in 
hyperglycemia and development of overt diabetes.  
2.2.3. Treatment of T2DM 
Dietary interventions, drugs, and surgical procedures have been used to treat 
T2DM. Reducing the size and increasing the frequency of carbohydrate feedings has 
been shown acutely to result in lower mean blood glucose and insulin levels over the day 
with the mechanism of slowing the rate of carbohydrate absorption [149]. Drugs, such as 
Metformin and Troglitazone, are the first-line drugs for the treatment of T2DM through 
activation of AMP-activated protein kinase (AMPK) [150] and nuclear receptor 
peroxisome proliferator-activated receptors (PPARs) [151], respectively. Bariatric 
surgery procedures have been shown to completely eliminate symptoms of associated 
with T2DM in human subjects [152]. New drugs have been consistently tested and 
pathways have been consistently explored for the intervention of T2DM. It has been 
shown that losing 10% of initial body weight can alleviate the symptoms of those diabetic 
subjects [153]. It seems to be so obvious that over consumption of nutrients contributes to 
the development of T2DM in human subjects. However, the roles of each micronutrient 
in development and treatment of T2DM have not been studied extensively. 
2.3. Insulin resistance 
2.3.1. Insulin secretion 
It has been known that the balance between insulin and glucagon, both secreted 
by pancreatic islets, regulates glucose homeostasis. After a meal containing carbohydrate, 
elevated blood glucose level stimulates pancreatic β-cells are to secret insulin to promote 
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glucose uptake and inhibit glucose release by the liver. When the blood glucose drops to 
a low level, glucagon is secreted from pancreas to increase blood glucose via the 
stimulation of gluconeogenesis. Glucose-stimulated insulin secretion (GSIS) is critical to 
maintain normal glucose levels and the impairment of GSIS is a key feature in T2DM 
[154]. Insulin secretion is also regulated by factors other than glucose. Physiologically 
elevated plasma FFAs potentiate GSIS resulting in elevated circulating insulin levels 
[155]. The insulinotropic effect increases and decreases with chain length and degree of 
unsaturation of FFAs, respectively [156]. Impaired GSIS was observed in VA deficient 
rats, which was improved with repletion [157]. All-trans RA has been shown to 
potentiate GSIS in insulin secreting INS-1 cells [158].  
2.3.2. Insulin resistance 
One common characteristic of obesity and T2DM is insulin resistance. Insulin 
resistance is the state in which cells are unable to response to the stimulation of insulin 
effectively leading to hyperglycemia. It has been known that insulin resistance is 
associated with increases in body weight. Reduction of body weight enhances insulin 
sensitivity in overweight/obese population and decreases the incidence of T2DM [159, 
160]. Additionally, variations in macronutrient content is also a potent factor affecting 
insulin action [161]. Consumption of high fat diet (HFD) impairs glucose uptake by 
muscle cells, which attributes to impaired GLUT4 translocation [162]. Elevated plasma 
FFAs has been considered the factor responsible for HFD-induced insulin resistance 
[163]. 
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2.3.3. Insulin signal transduction 
The active form of insulin consists of two chains that are linked by two disulfide 
bonds: the A chain contains an intrachain disulfide bridge and the B chain has a central 
helix [164]. Insulin receptor (IR) consists of two extracellular α-subunits and two 
intracellular β-subunits with tyrosine-kinase activity [164]. Insulin binds to the α-subunit 
of IR and activates the tyrosine-kinase activity of the β-subunit that selectively catalyzes 
the phosphorylation of itself and IR substrates (IRSs), which initiates the signal 
transduction [165-168]. Insulin signaling is transduced by multiple components in a 
complex network containing cascades of kinases and phosphatases [169, 170]. The 
insulin signaling event is further amplified via phosphatidylinositide 3-kinase 
(PI3K)/protein kinase B (PKB/Akt) pathway, and GRB2/mitogen-activated 
protein kinase (MAPK) pathway [171-173]. Another serine/threoine kinase that can be 
activated by PI3K is the atypical protein kinase C [174]. Human liver expresses several 
protein-tyrosine phosphatases (PTP) [175]. These components are shared by insulin-like 
growth factor (IGF) receptor and involved in mediating insulin and IGF signals [176]. 
2.4.  Insulin-mediated hepatic gene expression 
Insulin controls the expression of a variety of genes involved in glucose and lipid 
metabolism [177], including glycolysis, glycogenesis, gluconeogenesis, and lipogenesis. 
Insulin induces the expression of glucokinase gene (Gck) [178], the enzyme responsible 
for the first step of hepatic glycolysis, and suppresses the expression of 
phosphoenolpyruvate carboxykinase gene (Pck1) and glucose 6-phosphatase catalytic 
subunit (G6pc), the enzymes involved in the first and last steps of gluconeogenesis, 
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respectively [179]. Insulin also increases the expression levels of sterol regulatory 
element-binding protein 1c gene (Srebp-1c), a family member of SREBPs that regulate 
the hepatic cholesterol and fatty acid biosynthesis [180]. SREBPs induce the expression 
of fatty acid synthase gene (Fas) in hepatocytes and other tissue culture cells [181].  
2.4.1. Glucokinase (Gck) 
Hexokinases, found in different organisms ranging from bacteria to humans, are a 
family of enzymes that catalyze the initial phosphorylation of glucose to glucose-6-
phosphate (G6P) for the utilization of glucose in cells [182]. The tissue-specific 
isoenzyme forms of hexokinases catalyzing the same reaction differ in kinetics, 
regulatory mechanisms, and tissue localization [21]. Hexokinase II, in the skeletal muscle 
and other peripheral tissues, is coordinated with GLUT4 that specifically transports 
glucose in response to insulin stimulation to maintain a balance between glucose uptake 
and glucose phosphorylation [21]. Hexokinase IV, also known as glucokinase (GK), is 
the predominant hexokinase in both the liver and pancreatic β-cells. GK has a high Km 
for glucose (10 mmol/L) and its activity is linked to GLUT2, a high Km glucose 
transporter [21]. In the liver, GK serves as an insulin-dependent modulator of glucose 
utilization. During the period of rising glucose levels after a carbohydrate-containing 
meal, the increase of GK activity allows the phosphorylation of glucose thus maintaining 
a glucose concentration deficit for its entry. During the period of fasting, GK activity falls 
because of the declined insulin levels, thus reducing the glucose usage in the liver. In 
pancreatic β-cells, GK functions as a glucose sensor that controls the rate of insulin 
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secretion from β-cells. GK activity in pancreatic beta-cells is not affected by insulin, but 
by glucose levels [183, 184].  
The expression of GK is encoded by a single gene with two distinct cell-specific 
promoters: an upstream promoter regulates transcription of Gck in β-cells and certain 
neurons, and a downstream promoter controls transcription of Gck in the liver [178, 185]. 
The resulted GK proteins differ in amino acids encoded by their first exons. Thus, 
different Gck mRNAs are produced in these two tissues, resulting in two distinct GK 
isoforms. Therefore, they have specific tissue responses to hormonal and nutritional 
stimuli: β-cell GK activity is stimulated by glucose, whereas hepatic GK is induced by 
insulin and suppressed by cyclic AMP (cAMP) [178]. Short-term control of GK activity 
is regulated through binding to its regulatory protein [186],  phosphorylation by protein 
kinase A [187], or interaction with a cytosolic dual specificity phosphatase [188]. Long-
term regulation of GK activity is through transcription of its mRNA. Multiple 
transcriptional factor binding sites have been identified at the hepatic Gck promoter [189-
191]. SREBP-1c has been considered as the major mediator of insulin-induced Gck 
expression in hepatocytes [192]. However, recent studies from our lab and others have 
demonstrated that insulin-induced Gck expression occurs in a SREBP-1c independent 
manner [193].  
Mutations that alter the enzymatic activity of GK can result in maturity onset 
diabetes of the young (MODY) [194]. Transgenic knock-outs of Gck revealed that both 
β-cell GK and hepatic GK were essential for glucose homeostasis [195, 196]. Expression 
of GK in transgenic animals resulted in improved blood glucose and enhanced glucose 
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metabolism [197, 198]. Allosteric GK activators (GKAs) were demonstrated to increase 
the glucose affinity and maximum velocity (Vmax) of GK to augment GSIS and hepatic 
glucose metabolism [199]. Small molecule GKAs were reported to stimulate hepatic 
glucose metabolism by a mechanism independent of GK regulatory protein [200]. 
Therefore, GK is critical for the hepatic glucose metabolism and is a potential target for 
the treatment of diabetes.  
2.4.2. The cytosolic form of phosphoenolpyruvate carboxyl kinase (PEPCK-
C, Pck1) 
PEPCK catalyzes from the conversion of oxaloacetate to phosphoenolpyruvate, 
and PEPCK-C is essential for the hepatic gluconeogenesis [21]. The expression of the 
PEPCK-C gene (Pck1) can be detected in the liver, kidney, and adipose tissues [201]. A 
single gene encodes the cytosolic form of PEPCK with one promoter directing 
transcription of the gene, which is composed of a number of DNA response elements that 
are regulated by nutrients, hormones, and tissue-specific transcription factors [201]. The 
regulation of Pck1 gene expression is controlled by nutritional and hormonal stimuli 
[202]. It has been known that glucagon (acting via cAMP) and glucocorticoids induce 
Pck1 gene expression [203, 204], whereas insulin inhibits its expression [205]. The 
regulation of Pck1 transcription by insulin is probably by PI3K [206]. Fasting or 
starvation induces Pck1 mRNA levels while refeeding of a high-carbohydrate diet 
reduces its mRNA levels [207]. 
Transgenic mice over-expressing Pck1 developed insulin resistance and T2DM 
[208, 209]. Mice with the liver-specific deletion of Pck1 can preserve euglycemia during 
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starvation by increasing extrahepatic gluconeogenesis [210] but developed hepatic 
steatosis [211]. Mice with homologous deletion of Pck1 died with profound 
hypoglycemia and changes in lipid and amino acid metabolism were detected prior to 
death [212]. These results suggest that PEPCK-C is not only a regulator in hepatic 
gluconeogenesis but also impacts lipid metabolism. 
2.4.3. Sterol regulatory element-binding protein 1 (Srebp-1c)  
Insulin is required in hepatic utilization of glucose for lipogenesis in both normal 
and diabetic rats [213]. Feeding a high-carbohydrate, fat-free diet to fasted rats caused an 
increase in the quantity of enzymes involved in fatty acid synthesis, such as acetyl-CoA 
carboxylase (ACC) [214] and FAS [215]. Alloxan diabetic rats and poracaval-shunted 
rats had reduced levels of FAS in the liver while it returned to the normal range upon 
treatment of insulin [215]. The action of insulin on ACC and FAS is attributed to the 
changes at the mRNA level [216], which is regulated by two transcription factors, 
SREBP-1c and carbohydrate response element-binding protein (ChREBP) [217]. 
SREBPs play critical roles in lipid homeostasis due to their stimulation of the expression 
of more than 30 genes dedicated to the synthesis of cholesterol, fatty acids, and 
triacylglycerol [180]. SREBPs are generated as inactive precursors in the membrane of 
the endoplasmic reticulum (ER). The NH2-terminal domain of each SREBPs should be 
released from the membrane to reach the nucleus and activate target genes [180]. During 
this process, SREBP cleavage-activating protein (SCAP) escorts the SREBP from the ER 
to the Golgi apparatus, where the two proteases, S1P and S2P, cleave the SREBP to 
release the NH2-terminus [180]. SREBP has three isoforms, SREBP-1a, SREBP-1c, and 
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SREBP-2. Both SREBP-1a and -1c are derived from a single gene. SREBP-1c is a 
transcriptional factor for multiple genes for fatty acid synthesis, including ACC and FAS 
[181] while SREBP-2 preferentially activates cholesterol synthesis [192]. 
Studies have shown that the hepatic expression of SREBP-1c is stimulated by 
insulin and LXR ligands [218], and repressed by glucagon [219]. The effects of insulin 
on SREBP-1c are through enhancing transcription, increasing mobilization to the 
nucleus, and activating transcriptional activity [192]. Insulin responsive elements (IREs) 
in the Srebp-1c promoter are identified as two LXR binding elements (LXRE) and one 
sterol regulatory element (SRE) [220]. Maximal activation of Srebp-1c expression by 
insulin also requires specificity protein 1 (Sp1) to interact with other transcriptional 
factors [221]. PPAR binding element has been identified in the promoter of SREBP-1c 
and PPARα agonists act in cooperation with LXR or insulin to induce lipogenesis [222].   
Overexpression of SREBP-1c can mimic insulin effects on gene expression in 
hepatocytes [223]. Deletion of Srebp-1c severely impaired the induction of hepatic fatty 
acid synthetic genes in response to a cycle of fasting and refeeding [224]. Deletion of 
Srebp-1c in the liver diminished hepatic response to a fasting and refeeding cycle and 
LXR agonists [225]. All these studies demonstrate the importance of SREBP-1c in 
hepatic fatty acid synthesis. Evidence indicates that obesity is associated with increased 
hepatic lipogenesis [226] and the fatty liver of insulin resistant animals is accompanied 
by elevation of the expression of SREBP-1c [180]. Insulin selectively increases Srebp-1c 
mRNA in the livers of diabetic rats induced by the treatment of streptozotocin (STZ) 
[227]. Continuous activation of SREBP-1c transcription by insulin increases lipogenic 
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gene expression and further enhances fatty acid synthesis [228]. Insulin-independent 
signaling pathways can partially compensate for insulin in the induction of SREBP-1c by 
feeding, but further induction by obesity or T2DM is entirely dependent on insulin [229].  
2.5. Effects of VA on metabolism and the hepatic insulin-mediated gene 
expression 
In recent years, researchers have focused on the roles of VA status in the 
development of metabolic diseases. The importance of retinoid catabolism in hepatic 
glucose and lipid metabolism has gradually become more apparent. As early as 1937, 
when VA reserve in the liver was analyzed, it was observed that its level was elevated in 
patients with diabetes [230]. The loss of the carcass fat was observed in VA deficient 
(VAD) rats [231], but cholesterol content was not affected by VA status [232]. Feeding 
rats with all-trans and 13-cis RA induced hypertriglyceridemia, suggesting the roles of 
retinoids in the regulation of plasma TG clearance or secretion from the liver [233]. 
Patients who received isotretinoin (13-cis RA) for the treatment of their acne developed 
isotretinoin-induced hypertriglyceridemia [234]. Systemic therapy with tretinoin (all-
trans RA) for human also caused massive hypertriglyceridemia [82].  
On the other hand, all-trans RA treatment in mice was observed to effectively 
reduce the body weight, which was probably due to decreased expression of genes 
involved in hepatic lipogenesis [235] and remodeling of white adipose tissue [236]. 
Additionally, all-trans RA has been shown to repress obesity and insulin resistance by 
activating PPARβ/δ and RAR [237]. Recently, RA was reported to inhibit adipogenesis 
by activating the CRABP-II/RARγ pathway in preadipose cells [238]. All these 
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observations demonstrated the relationship between VA and glucose and lipid 
metabolism.  
It has been reported that all-trans RA induces the Gck expression in rat 
hepatocytes in the absence of insulin [239]. Recently, we have reported that retinoids 
synergize with insulin to induce Gck expression [240]. RA was reported to increase the 
rate of transcription of Pck1 in primary hepatocytes with RAREs located in the Pck1 
promoter [241, 242]. We reported that retinoids induce Pck1 expression and attenuate 
insulin-mediated suppression of its expression in primary rat hepatocytes [243].  
VA status affects obesity development in Zucker fatty (ZF) rats and VAD rats had 
reduced plasma TG levels and decreased Srebp1-c mRNA levels [244]. RA synergizes 
with insulin to induce the expression of Srebp1-c in primary rat hepatocytes through the 
activation of RXR and previously identified LXREs in the Srebp-1c promoter are also 
RAREs [245]. Thus, further studies should be done to investigate the effects of RA on 
insulin-mediated expression of genes that are involved in hepatic glucose and lipid 
metabolism. 
In addition to RA, the enzymes involved in RA biosynthesis are also observed to 
participate in lipid metabolism. The Raldh1 knockout mice are resistant DIO and insulin 
resistance [56], which may attribute to the elevated retinal contents in adipose tissues that 
suppress the adipogenesis via retinal-inhibited activation of PPARγ and RXR [56]. 
RALDH1 was also observed to be up-regulated in both the kidney and the liver of 
diabetic mice despite decreased RA levels in association with a decrease in PPAR β/δ 
[57]. Feeding mice with high cholesterol diet stimulated the hepatic expression of 
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RALDH1 and RALDH2 through oxysterol-induced Srebp-1c expression, indicating the 
interaction of cholesterol and RA metabolism [65]. All these observations indicate the 
potential roles of these enzymes in the development of obesity and insulin resistance, 
which deserves to be investigated. 
Thus, we hypothesize that VA contributes to the regulation of expression of 
hepatic genes in glucose and lipid metabolism. Enzymes involved in RA biosynthesis 
may also contribute to the regulation through the control of RA production. Whether the 
dietary VA from food or the stored VA in the liver plays the major role in the regulation 
of gene expression deserves to be investigated 
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Chapter Two 
Elevated hepatic Raldh1 expression in Zucker fatty rats and its over-expression 
introduced retinal-induced Srebp-1c expression in INS-1 cells 
1. Introduction 
The high obesity prevalence in the population of the United States [246] is 
predictive for type 2 diabetes mellitus (T2DM) [247], a major public health concern 
[248]. Genetic mutations, such as mutations of leptin and its receptor, have been shown 
to cause the development of obesity and diabetes [249]. Currently, the associations of a 
variety of genes with the development of human obesity or T2DM have been identified 
[250, 251]. Metabolic abnormalities are often associated with profound changes of 
hepatic glucose and lipid metabolism [252], which are attributed, at least in part, to the 
expression of genes involved in these processes [228, 253]. On the other hand, 
overconsumption of nutrients, such as fructose in sweetened beverages, has also been 
implied to play a role in the rise of obesity [138]. Dietary nutrients provide not only 
energy, but also vitamins and other essential factors with regulatory roles. The effects of 
individual micronutrients on the development of metabolic diseases remain to be 
revealed.  
As an essential and fat-soluble micronutrient, vitamin A (VA, retinol) plays 
crucial roles in the general health of an individual, such as vision, tissue differentiation, 
and immunity [254]. The majority of the physiological actions of retinol are mediated by 
its active metabolite, retinoic acid (RA), which exists in multiple isomeric forms, such as 
all-trans RA and 9-cis RA [255]. RA regulates gene expression through the activation of 
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two families of nuclear receptors, retinoic acid receptors (RARα, β and γ) activated by 
all-trans RA, and retinoid X receptors (RXRα, β and γ) activated by 9-cis RA [256].  
In an attempt to understand the effects of endogenous lipophilic molecules on the 
insulin-regulated gene expression in primary rat hepatocytes, we have analyzed the rat 
liver lipophilic extract and found that retinol and retinal in it dose-dependently induced 
the mRNA expression levels of Pck1 [243], Gck [240], and Srebp-1c [245]. The proximal 
one of the two previously identified retinoic acid response elements (RAREs) in Pck1 
promoter [241, 257, 258] mediates the RA effect in primary hepatocytes. The previously 
identified two liver X receptor (LXR) binding sites mediating the insulin-stimulated 
Srebp-1c expression [220] were also RAREs in its promoter [245], demonstrating the 
convergence of hormonal and nutritional responses. The hepatic expression level of 
cannabinoid receptor 1 (CB1), the target of anti-obesity drug Rimonabant [259] can also 
be induced by the treatment of RA via activation of RAR-γ [260], indicating the 
connection between the endocannabinoid pathways and the nutritional signals. The 
effects of VA status on glucose and lipid metabolism have been summarized in details 
[111]. 
Retinol is reversibly oxidized into retinal by retinol dehydrogenases (RDHs). 
Retinal is irreversibly oxidized into RA by retinaldehyde (aldehyde) dehydrogenases 
(RALDHs) [256, 261, 262]. Currently, four RALDHs have been cloned and thought to be 
responsible for all-trans or 9-cis RA production in various tissues [49, 51, 66, 263]. 
RALDH1-4 proteins can be detected in some but not all hepatocytes of the mouse liver 
using immunohistochemistry, with RALDH1 being frequently expressed in lipid-
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engorged cells [51]. Raldh1 (also known as Aldh1a1) mRNA is expressed weakly in the 
rat liver [263], whereas Raldh4 (also known as Aldh8a1) mRNA is expressed at high 
level in the mouse liver [51]. The mice with Raldh1 deletion (Raldh1-/-) have reduced 
RA production in the liver 2 hr after a challenge of retinol [264]. The Raldh1-/- mice are 
resistant to diet-induced obesity (DIO) and insulin resistance [56]. The Imprinting 
Control Region (ICR) mice fed a high cholesterol diet had elevation of the hepatic 
expression of RALDH1 and RALDH2 through oxysterol-induced Srebp-1c expression, 
demonstrating the interaction of cholesterol and RA metabolism [65]. All these 
observations indicate the potential roles of these enzymes in the development of obesity 
and insulin resistance, which deserves to be further defined. 
The fact that the levels of the enzymes for the hepatic retinoid metabolism can be 
dynamically regulated leads us to hypothesize that the change of the expression of these 
enzymes and the production of RA may contribute to the regulation of the expression of 
hepatic lipogenic genes. Here, we examined the effects of retinol and retinal on the 
expression of RA responsive genes in primary rat hepatocytes, rat hepatoma cells and 
insulinoma INS-1 cells. We observed the elevated expression levels of Raldh1 mRNA in 
hepatocytes and its protein in the liver of Zucker fatty (ZF) rats. The recombinant 
adenovirus-mediated over-expression of RALDH1 resulted in retinal-mediated induction 
of Srebp-1c expression in INS-1 cells, which originally lack the response to retinal.  
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2. Materials and Methods 
2.1. Reagents  
The reagents for primary hepatocyte isolation and culture have been published 
previously [265]. Source of LG268 was reported previously as well [240]. All other 
compounds were purchased from Sigma (St. Louis, MO) unless described otherwise. The 
reagents for cDNA synthesis and real-time PCR were obtained from Applied Biosystems 
(Foster city, CA). Medium 199, liver perfusion medium and liver digest buffer were 
obtained from Invitrogen (now Life Technologies, Grand Island, NY 14072). Dulbecco’s 
Modification of Eagle Medium (DMEM), RPI-1640 medium, fetal bovine serum, 
antibiotics, and trypsin-EDTA solution were obtained from Fisher Scientific (Pittsburgh, 
PA 15275). 
2.2. Animals  
Male Sprague-Dawley (SD) rats were purchased from Harlan Breeders 
(Indianapolis, IN). Male Zucker lean (ZL) and ZF rats were bred at UTK. Rats were 
housed in colony cages, and fed a standard rodent diet before isolation of primary 
hepatocytes. All procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Tennessee at Knoxville (Protocol numbers 1642 and 
1582).  
2.3. Cultures of primary rat hepatocytes, HL1C rat hepatoma cells, 293 human 
embryonic kidney cells, and INS-1 rat insulinoma cells 
Methods for the primary rat hepatocyte preparation and analysis of RNA were 
described previously [265]. For the hepatocyte isolation and pretreatment, the rats were 
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euthanized with carbon dioxide. A catheter was inserted into portal vein and connected to 
a peristaltic pump with liver perfusion medium and liver digestive buffer. The inferior 
vena cava was cut open to allow the outflow of the media at 10 ml/min. After completion 
of the perfusion, the liver was excised and put into a tissue culture dish containing liver 
digestive buffer for removing the connection tissues and allowing the release of 
hepatocytes. The medium containing hepatocytes was filtered through a cell strainer (100 
µm), and precipitated by 50×g centrifugation for 3 min. The cell pellet was washed twice 
with DMEM containing 5% fetal bovine serum (FBS), 100 U/ml sodium penicillin, and 
100 µg/ml streptomycin sulfate after re-suspension and precipitation. After the wash, the 
isolated hepatocytes were plated onto 60 mm collagen type I coated dishes at 3×106 cells/ 
per dish and incubated in 4 ml of the same medium at 37°C and 5% CO2 for 3 to 4 hr. 
The attached cells were washed once with 4 ml of PBS, and incubated in medium A 
(Medium 199 supplemented with 100 nM dexamethasone, 100 nM 3, 3′, 5-triiodo-L-
thyronine (T3), 100 units/ml penicillin, and 100 µg/ml streptomycin sulfate) containing 1 
nM insulin for overnight (14–16 hr) until being used for the indicated experiments.  
The HL1C cells [266] which was stably transfected with a reporter gene construct 
containing a fragment of Pck1 promoter sequence were kindly provided by Dr. Donald K. 
Scott at University of Pittsburgh. They were maintained in DMEM containing 4.5 g/L 
glucose, 4% FBS, 100 U/ml of penicillin and 100 µg/ml streptomycin sulfate. They were 
incubated in 60 mm dishes with serum free DMEM containing the indicated reagents 
shown in the figure legends for the indicated length of time before being subjected to 
analysis. 
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The 833/15 and 834/40 clonal insulinoma INS-1 cells [267] were cultured in 
medium B (RPMI 1640, 2 mM L-glutamine, 1 mM Na-pyruvate, 50 µM β-
mercaptoethanol, 100 U/ml of penicillin and 100 µg/ml streptomycin sulfate) containing 
10% FBS as described previously. For the treatment, INS-1 cells in 60 mm dishes were 
incubated in medium B containing the indicated reagents shown in the figure legends for 
the indicated length of time before being subjected to analysis. 
The HEK293 cells were cultured in DMEM containing 4.5 g/L glucose, 8% FBS, 
100 U/ml of penicillin and 100 µg/ml streptomycin sulfate at 37ºC and 5% CO2.  
2.4. RNA extraction and quantitative real-time PCR  
Total RNA was extracted from the treated cells on one 60 mm dish using 1 ml of 
RNA STAT 60 reagent (TEL-TEST, Inc, Friendswood, TX) according to the 
manufacture’s protocol. The contaminated DNA was removed using the DNA-freeTM kit 
(Applied Biosystems). First strand cDNA was synthesized from 2 µg of DNA-free RNA 
with random hexamer primers using cDNA synthesis kit (Applied Biosystems). The real-
time PCR primer sequences for detecting Cyp26a1 [268], Srebp-1c [245], and Raldh1 
[269] have been reported previously. The primers for detecting Rdh2 (sense 5’-
CAAGTTCTTCTACCTCCCCATGA-3’, and anti-sense 5’-
TCCAGTAGAAAAGGGCATCCA-3’) were designed using software Primer Express 
3.0 (Applied Biosystems). Each SYBR green based real-time PCR reaction contains, in a 
final volume of 14 µl, cDNA from 14 ng of reverse transcribed total RNA, 2.33 pmol 
primers, and 7 µl of 2× SYBR Green PCR Master Mix (Applied Biosystems). Triplicate 
PCR reactions were carried out in 96-well plates using 7300 Real-Time PCR System. The 
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conditions are 50ºC for 2 min, 95ºC for 10 min, followed by 40 cycles of 95ºC for 15 
seconds (s) and 60ºC for 1 min. The gene expression level was normalized to that of 
invariable control gene, 36B4. Data are presented as either minus ∆ cycle threshold CT 
[270] or the induction fold for which the control group is arbitrarily assigned a value of 1 
using ∆∆CT method as previously described [265].  
2.5. Cloning of the rat Raldh1 cDNA and generating Ad-Raldh1 recombinant 
adenovirus for the over-expression of RALDH1 
To clone the rat Raldh1 cDNA, sense 5’-AGCCAAACCAGCAATGTCTTC-3’, 
and anti-sense 5’-CACTCTGCTTCTTAGGAGTTC-3’ primers were designed based on 
its mRNA sequence (reference number NM_022407.3) from the National Center for 
Biotechnology Information. The Raldh1 cDNA containing the entire coding sequence 
was amplified using SD rat primary hepatocyte cDNA as a template. The amplicon was 
ligated into pCR®2.1 vector through TA Cloning® Kit (Invitrogen) and processed 
according to the manufacture’s protocol. The full-length cDNA with the correct sequence 
confirmed by DNA sequencing was inserted to pACCMV5 for making pACCMV5-
Raldh1. 
To generate Ad-Raldh1 recombinant adenovirus, plasmids pACCMV5-Raldh1 
and JM17 were co-transfected into 293 cells using FuGENE®6 Transfection Reagent 
(Roche Applied Science, Indianapolis, IN). Transfected 293 cells were incubated in 
DMEM containing 2% FBS at 37ºC and 5% CO2 until the formation of the plaques due to 
the lysis of the cells. The crude lysate was collected and stored at -80ºC. The presence of 
Raldh1 cDNA sequence in the viral DNA was confirmed by PCR. 
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2.6. Preparation and purification of recombinant adenoviruses 
To generate the crude lysate, HEK 293 cells grew in 100 mm tissue culture plates 
at 80% confluence were infected by the original crude lysate containing Ad-Raldh1. The 
ratio of the medium to crude lysate is 10 to 1. After the lysis of the cells at around 48 hr 
post infection, the cell culture medium (the crude lysate) was collected, and stored at -
80ºC until being used.  
For purification of the recombinant adenovirus, NP-40 was first added into the 
crude lysate to reach the final concentration at 0.5%. The mixture was shaken gently at 
room temperature for 30 min and subjected to centrifugation at 8,000 rpm and 4ºC for 15 
min. The supernatant was transferred to a clean bottle, and 0.5× volume of 20% 
PEG8000/2.5 M NaCl was added. The preparation was shaken gently at 4ºC overnight. 
The resulting mixture was transferred to centrifuge bottles and spun at 13,000 rpm at 4ºC 
for 15 min.  The precipitated pellet was re-suspended in a small volume of PBS (2-3 ml), 
and spun at 8,000 rpm and 4ºC for 10 min to remove insoluble matters. Solid CsCl was 
added to the supernatant until its final density reached 1.34 g/ml. The mixture was spun 
at 90,000 rpm and 25ºC for 3 hr using OptimaTM MAX-XP Ultracentrifuge (Beckman 
Coulter, Inc.). The corresponding band containing pure viral particles was collected in a 
total volume less than 1 ml for desalting. The PD-10 column SephadexTM G-25M 
(Amersham Pharmacia Biotech AB, Sweden) was equilibrated with 5 ml PBS. The 
purified virus in CsCl solution was loaded onto the column and eluted with 5 ml PBS. 
The flow through was collected into ten fractions. The optical densities (OD) at 260 nm 
of these fractions were determined using Spectronic® GENESYSTM 5 Spectrophotometer 
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(Thermo Scientific). The fractions containing significant values of absorbance (usually at 
around fractions 7-9) were collected and pooled. Bovine serum albumin and glycerol 
were added to the pooled solution to make the stock viral solution with the final 
concentrations of them at 0.2% and 10%, respectively. After the filtration of the stock 
solution for sterilization, its OD was determined to estimate the plaque forming units 
(pfu). We used that 1 OD equals to 1×1012 pfu/ml. The final purified virus stock was 
frozen at -80ºC until being used in the indicated experiments. 
2.7. Immuno-blot and quantification of the protein bands 
INS-1 cells were infected with purified Ad-Raldh1 for 24 hr. The cells in 60 mm 
dishes were washed once with 3 ml PBS and scrapped from the dish into 400 µl of 
whole-cell lysis buffer (1% Triton X-100, 10% glycerol, 1% IGEPAL CA-630, 50 mM 
Hepes, 100 mM NaF, 10 mM EDTA, 1 mM sodium molybdate, 1 mM sodium β-
glycerophsphate, 5 mM sodium orthovanadate, 1.9 mg/ml aprotinin, 5 µg/ml leupeptin, 1 
mM benzamide, 2.5 mM PMSF, pH 8.0). The lysates were placed on ice for at least 20 
min before they were subjected to centrifugation at 13,000 rpm for 20 min. The protein 
concentration in the supernatant was determined with PIERCE BCA protein assay kit 
(Rockford, IL). Proteins (40 µg/lane) in whole cell lysates were separated on SDS-PAGE, 
transferred to BIO-RAD Immuno-Blot PVDF membrane (Hercules, CA) and detected 
with primary antibodies to RALDH1 (for Figure 2-5, catalog #2052-1, Epitomics, 
Burlingame, CA 94010), RALDH1 (for Figure 2-1, catalog #AP1465a, Abgent, San 
Diego, CA 92121), CYP26A1 (catalog # CYP26A11-A, Alpha Diagnostics International, 
TX 78244), and β-Actin (#4970s, Cell Signaling Technology, Danvers, MA 01923) 
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according to the protocols provided by the manufacturers. Bound primary antibodies 
were visualized by chemiluminescence (ECL Western Blotting Substrate, Thermo 
Scientific) using a 1:2,000 dilution of goat anti-rabbit IgG (#7074P2, Cell signaling 
Technology) conjugated to horseradish peroxidase. Membranes were exposed to X-ray 
films (Phenix Research Products, Candler, NC) for protein band detection. The films 
were scanned using an HP Scanjet 3970 (Palo Alto, CA 94304) and stored as Tagged 
Image File Format (TIFF). The ImageJ Software (http://rsbweb.nih.gov/ij/) was used to 
determine the density of a protein band by subtracting the background in an area of the 
same size immediately in front of protein band. The ratio of the densities of RALDH1 
and β-Actin in the same sample was calculated and used for statistical analysis.  
2.8. Statistics    
Data are presented as means ± S.D. The number of experiments represents the 
independent experiments using hepatocytes isolated from different animals or indicated 
cells cultured in different days. Levene’s test was used to determined homogeneity of 
variance among groups using SPSS 19.0 statistical software and where necessary natural 
log transformation was performed before analysis. An independent-samples t-test was 
used to compare two conditions. Multiple comparisons were analyzed by one-way 
analysis of variance (ANOVA) using least significant different (LSD) when equal 
variance was assumed, and Games-Howell test was used when equal variance was not 
assumed. Differences were considered statistically significant at P < 0.05. 
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3. Results 
3.1. Determination of the mRNA levels of enzymes responsible for the retinoids 
catabolism in primary hepatocytes, and the elevated expression of Raldh1 and its 
protein in hepatocytes of ZF rats 
Enzymatic processes are involved in the conversions of retinol to retinal and 
retinal to RA [256, 261, 262]. It has been shown that the short chain 
dehydrogenase/reductase family 16C member 5 (SDR16C5), RDH2, RDH10, and 
RALDH1-4 are expressed in the liver [271]. Since RALDH4 is for the biosynthesis of 9-
cis RA [51], we have focused on the expression levels of the rest of the enzymes in this 
study. The CT numbers of these genes were normalized to those of 36B4 (an invariable 
control gene) in the same samples. Based on -∆CT numbers (how close the abundance of 
the transcripts of those genes to that of 36B4), we found that Rdh2, and Raldh1 were 
expressed in meaningful levels (compared with the expression level of 36B4) in both 
primary rat hepatocytes and HL1C cells (data not shown).   
Since RDH2 catalyzes the conversion of retinol to retinal, and RALDH1 is 
reponsible for converting retinal to RA [271], we compared their expression levels in 
freshly isolated primary hepatocytes of ZL rats with those of ZF rats. The mRNA level of 
Rdh2 in hepatocytes from ZF rats was similar to that from ZL rats. However, the mRNA 
level of Raldh1 in hepatocytes from ZF rats was significantly higher than that from ZL 
rats (Figure 2-1A). The results observed in cultured primary hepatocytes of ZL and ZF 
rats were similar to that in fresh isolated hepatocytes. We observed that the Rdh2 
expression level was unchanged, and the Raldh1 expression level was elevated 
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significantly in hepatocytes from ZF rats (Figure 2-1B). The mRNA level of Raldh4 was 
detected, and was at the similar levels in hepatocytes from both ZL and ZF (data not 
shown). 
Figure 2-1C shows that the RALDH1 protein levels in the liver samples of ZF rats 
were higher than that of ZL rats. Since two protein bands migrating close to each other 
were detected in the Immuno-blot, the lysate of INS-1 cells infected by recombinant 
adenovirus Ad-Raldh1 expressing RALDH1 protein was used as the control to determine 
the correct size of it. Based on the size of the control sample, the lower band detected by 
the antibody should be the correct one in the liver samples. Their densities were 
normalized to the densities of the β-Actin in the same samples. The quantified data were 
presented as the ratios of RALDH1/β-Actin as shown in Figure 2-1C. The ratios of ZF 
rats are significantly higher than that of ZL rats, demonstrating that the elevation of 
Raldh1 mRNA corresponds with an induction of RALDH1 protein. 
3.2. Retinoids induced the expression levels of Cyp26a1 mRNA in primary rat 
hepatocytes 
To demonstrate that retinoids catabolism can contribute to the regulation of gene 
expression in primary rat hepatocytes, the expression levels of Cyp26a1 mRNA (a RA 
responsive gene) in response to retinol (ROL) and retinal (RAL) treatments were 
determined using real-time PCR. Figure 2-2A shows a 24-hour time course of the 
expression levels of Cyp26a1 mRNA in Sprague-Dawley (SD) rat primary hepatocytes 
treated with 5 µM RA. More than 1000-fold induction of Cyp26a1 mRNA level was 
observed at 3 hr after the RA treatment, the earliest time point checked. The Cyp26a1 
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mRNA level was further induced at 6 hr and maintained elevated at 12 hr after treatment. 
At 24 hr after the treatment, its level dropped comparing to that at 12 hr, but still 
remained significantly higher than that at time 0. 
To determine the effects of retinol and retinal on the induction of Cyp26a1 
expression, primary rat hepatocytes from SD rats were treated with increasing 
concentrations of retinol or retinal for 6 hr. As shown in Figure 2-2B, the levels of 
Cyp26a1 mRNA were induced by retinol and retinal in a dosage dependent manner. 
retinol and retinal started to induce Cyp26a1 expression at 2 µM and 0.02 µM, 
respectively. When the induction folds of Cyp26a1 expression in response to retinol and 
retinal treatments were compared, retinal groups had significantly higher values than 
retinol groups did at concentrations of 0.02 µM, 0.2 µM, 2 µM, and 20 µM. It suggests 
that retinal is more readily converted to RA than retinol to induce Cyp26al expression.  
3.3. Inhibition of RAR activation blocked the RAL-mediated induction of 
Cyp26a1 expression in primary rat hepatocytes 
We have shown that the activation of RAR or/and RXR can induce Cyp26a1 
expression [272]. To confirm the involvement of RAR activation in the RAL-mediated 
induction of Cyp26a1 expression, primary SD rat hepatocytes were treated with 
increasing concentrations of Ro 41-5253, a specific antagonist for RAR activation [273]. 
As shown in Figure 2-2C, retinal at 2 µM dramatically induced the Cyp26a1 expression, 
further confirming the result shown in Figure 2-2B. This induction was dose-dependently 
inhibited with increasing concentrations of Ro 41-5253. When the concentration of Ro 
41-5253 reached 10 µM or higher, the induction of Cyp26a1 expression by retinal was 
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completely suppressed. This reverse association between the concentration of Ro 41-
5253 and the induction of Cyp26a1 expression by retinal demonstrated that the inhibition 
of RAR activation disrupted the retinoid-mediated induction of Cyp26a1 expression in 
primary hepatocytes, indicating the important role of RAR activation in this induction.  
3.4. Retinoids induced the expression levels of Cyp26a1 mRNA and CYP26A1 
protein in HL1C rat hepatoma cells through the activation of RAR and RXR 
To screen for cultured cell lines which we can study the effects of retinoid 
metabolism on the expression of RA responsive gene, we analyzed the expression of 
Cyp26a1 mRNA and CYP26A1 protein in response to ROL, retinal and RA treatments in 
HL1C rat hepatoma cells, a cell line that responds to insulin stimulation [274]. Figure 2-
3A shows the expression levels of Cyp26a1 mRNA in HL1C cells treated with the 
indicated concentrations of retinoids. ROL, retinal and RA started to induce Cyp26a1 
mRNA expression at 20 µM, 2 µM, and 0.2 µM, respectively, demonstrating the different 
potencies of these retinoids. At 2 µM or 20 µM, the fold induced by retinal was 
comparable to that by RA. The highest induction fold of Cyp26a1 mRNA mediated by 
RA in HL1C cells was near 300-fold which was much lower than that in primary 
hepatocytes (1000-fold) as shown in Figure 2-2. The effects of retinal and RA on 
Cyp26a1 mRNA expression in HL1C cells over a 24-hour time period were also 
examined as shown in Figure 2-3B. Both retinal and RA induced Cyp26a1 mRNA 
expression as early as 3 hr. At 6 hr after the treatment, the elevated level of Cyp26a1 
mRNA began to drop in comparison to its level at 3 hr. At 9, 12, and 24 hr time points, its 
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level further declined, but remained significantly higher than that at time 0. The induction 
was still elevated at 24 hr after treatment.  
To examine whether the activation of RAR or RXR was sufficient for the 
induction of Cyp26a1 mRNA expression, HL1C cells were treated with TTNPB, LG268, 
and T1317, agonists for RAR, RXR and LXR activation, respectively. As shown in 
Figure 2-3C, the induction folds of the TTNPB, LG268 and T1317 groups are 183.0 ± 
60.0, 8.0 ± 3.8, and 1.0 ± 0.4. These results demonstrated that the activation of RAR and 
RXR, but not LXR, induced the Cyp26a1 mRNA expression in HL1C cells, indicating 
that RA activated both RAR and RXR to induce Cyp26a1 mRNA expression. The 
induction fold of TTNPB group is much higher than that of LG268 group, similar to that 
observed in primary hepatocytes [245].  
Figure 2-3D shows the expression levels of CYP26A1 protein in HL1C cells 
treated with retinal or RA for 12 and 24 hr. The equal loading of protein samples was 
confirmed by the similar levels of β-Actin protein among the samples. This result 
demonstrated that the induction of Cyp26a1 mRNA resulted in significant elevation of 
CYP26A1 protein at both time points. All our results suggest that retinol and retinal may 
be converted to RA, which causes the RAR activation and the subsequent induction of 
Cyp26a1 mRNA and CYP26A1 protein levels in HL1C cells.  
3.5. RA, but not RAL, induced the Srebp-1c expression through the activation of 
RXR, but not RAR, in INS-1 rat insulinoma cells 
We have screened the cultured cell lines in which retinal does not induce Srebp-
1c expression for a tool to study the conversion of retinal to RA, and shown that RA, but 
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not RAL, induced the Srebp-1c expression dose-dependently in 833/15 INS-1 cells [245]. 
To further confirm that INS-1 cells are an ideal tool to study the conversion of retinal to 
RA, we analyzed the effects of retinal and RA on Srebp-1c expression in 834/40 INS-1 
cells, another clonal INS-1 cells [267]. Figure 2-4A shows that RA started to significantly 
induce the Srebp-1c expression at 0.1 µM while retinal did not change its expression at 
any concentration tested. Figure 2-4B shows the induction of the Srebp-1c expression by 
RA in 834/40 INS-1 cells over a 24-hour time period. RA, but not RAL, induced the 
Srebp-1c expression as early as 3 hr and peaked at 6 hr. At 9, 12, and 24 hr, the induction 
folds declined in comparison to that at 3 and 6 hr, but still maintained significantly higher 
than that at 0 hour. These results and the results shown previously [245] indicate that 
INS-1 cells may lack the enzymatic activities that convert retinal to RA. 
To determine whether the activation of RAR or RXR mediates the effects of RA 
on the Srebp-1c expression, INS-1 cells were treated with TTNPB (1 µM), LG268 (1 
µM), or TTNPB + LG268 for 6 hr. Figure 2-4C shows that LG268 and LG268 + TTNPB 
induced the Srebp-1c expression while TTNPB alone did not induce it. Thus, RXR 
activation mediates the RA-induced Srebp-1c expression in INS-1 cells. All these results 
demonstrated that the RA-mediated activation of RXR caused the induction of Srebp-1c 
in INS-1 cells, which makes INS-1 cell lines an ideal tool to study the role of RA 
production in the regulation of lipogenic gene expression. 
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3.6. The over-expression of RALDH1 resulted in the RAL-mediated induction of 
Srebp-1c in INS-1 cells 
To further study the effects of the elevated Raldh1 mRNA expression in ZF 
hepatocytes, its full-length cDNA was cloned and inserted it into pACCMV5 for the 
generation of recombinant adenovirus Ad-Raldh1. As shown in Figure 2-5, INS-1 cells 
infected with Ad-Raldh1 had the over-expression of Raldh1 mRNA (Figure 2-5A) and 
RALDH1 protein (Figure 2-5B). The equal loading of the protein samples was confirmed 
by the similar levels of β-Actin protein among the samples. In INS-1 cells infected with 
Ad-Raldh1 for overnight (~18 hr), but not in those infected with Ad-β-gal, retinal started 
to significantly induce the Srebp-1c expression at both 0.3 µM and 1 µM (Figure 2-5C). 
On the other hand, RA induced the Srebp-1c expression in cells infected by either Ad-β-
gal or Ad-Raldh1 (Figure 2-5D). In those cells with the over-expression of RALDH1, the 
induction folds of Srebp-1c by retinal treatment were comparable to that by RA. These 
results indicate that the over-expression of RALDH1 introduced the RAL-mediated 
induction of Srebp-1c in INS-1 cells, indicating the successful conversion of retinal to 
RA. 
 
4. Discussion 
In insulin resistant animals, hyperinsulinemia is associated with elevated hepatic 
gluconeogenesis and lipogenesis, which should be respectively suppressed and stimulated 
by insulin [275]. Our lab has shown that retinoids regulate the expression levels of genes 
involved in hepatic glucose and fatty acid metabolism. These regulations contribute to the 
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modulation of insulin-mediated expression of these genes in primary hepatocytes [240, 
243, 245]. The implication of these observations is that the dynamic regulation of RA 
production may be responsible for hepatic insulin resistance.  
To confirm that the treatments of retinol and retinal can regulate gene expression 
presumably through the production of RA, we analyzed the expression levels of 
Cyp26a1, an RA responsive gene [268], in primary hepatocytes (Figure 2-2). Retinoids 
induced the expression of Cyp26a1 in a dose- and time-dependent manner. This induction 
can be blocked in the presence of RAR antagonist, indicating the requirement of RAR 
activation. This result and the fact that retinal induced the Cyp26a1 expression indicate 
that RA production occurs.  
To find the cultured cell lines that can be used as tools for further studies of the 
retinoid catabolism, we have analyzed the retinoid-mediated gene expression in HL1C rat 
hepatoma cells (Figure 2-3). Retinol, retinal, and RA also induced the expression levels 
of Cyp26a1 mRNA in HL1C cells in a dose- and time-dependent manner, which is 
similar to the results obtained in primary hepatocytes. This induction is mediated by the 
activation of RAR and RXR. The induction of Cyp26a1 mRNA results in the elevated 
levels of CYP26A1 proteins in HL1C cells. However, the elevated levels of CYP26A1 
protein are not as high as that of Cyp26a1 mRNA at 12 and 24 hr (Figure 2-3B and D), 
indicating the potential roles of protein translation and/or stability in the determination of 
the CYP26A1 protein levels in HL1C cells. The maximal induction folds by reintoids are 
higher in primary hepatocytes than in HL1C cells. Retinol and retinal respectively induce 
the expression of Cyp26a1 mRNA at 2 and 0.02 µM in primary hepatocytes and at 20 and 
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2 µM in HL1C cells. These results indicate that primary hepatocytes seem to be more 
readily to convert retinol to retinal and then to RA. Alternatively, HL1C cells are more 
readily to convert retinal to retinol so that less RA is generated. Whether it is true or not 
deserves further investigation. It also indicates that HL1C cells can be used as a tool to 
study the metabolism of retinoids and its effects on the regulation of the expression of 
RA responsive genes.  
It has been shown that the short chain dehydrogenase/reductase family 16C 
member 5 (SDR16C5), RDH2, RDH10, RALDH1-4 are expressed in the liver [271]. 
Since Raldh4 mRNA (encoding RALDH4) is for the production of 9-cis RA [51], we 
focused on Rdh2 and Raldh1. Their mRNA levels in both freshly isolated and cultured 
primary hepatocytes of ZL and ZF rats were compared. The mRNA level of Raldh1, but 
not that of Rdh2, is higher in ZF than that in ZL rat hepatocytes. In addition, the hepatic 
RALDH1 protein level is also higher in ZF rats than in ZL rats (Figure 2-1). The elevated 
expression levels of Raldh1 mRNA and RALDH1 protein levels may be resposible for 
the altered hepatic lipogenesis in ZF rats. To test the hypothesis, we made recombinant 
adenovirus Ad-Raldh1 to over-express RALDH1 protein in INS-1 rat insulinoma cells. 
We have shown previously [245] and here (Figure 2-4) that RA, but not RAL, induced 
Srebp-1c expression in INS-1 cells. It seems that INS-1 cells lack the enzymatic activities 
converting retinal to RA. This makes INS-1 cells an ideal tool to test our hypothesis that 
the elevated expression of RALDH1 in ZF rats causes the increase of RA production, and 
in turn, the induction of RA responsive gene expression. After the over-expression of 
Raldh1 mRNA and RALDH1 protein in INS-1 cells, retinal started to induce the Srebp-
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1c expression as RA did. This indicates that retinal was oxidized to RA by RALDH1 
before the induction of Srebp-1c. The elevated levels of hepatic Raldh1 mRNA and 
RALDH1 protein in ZF rats may contribute to the regulation of hepatic lipogenesis.  
It has been shown that the mRNA level of Raldh1 is elevated in the kidney of 
db/db mice [57]. Both db/db mice and ZF rats develop obesity due to the mutation of 
leptin receptor [249]. It has been shown that ICR mice fed high cholesterol diet have the 
elevated expression levels of Raldh1 and Raldh2. This is attributed to the oxysterol-
induced expression of SREBP-1c which directly binds to the sterol regulatory response 
elements (SREs) at the proximal promoter regions of Raldh1 and Raldh2, and induces 
their expression [65]. Since the expression of Srebp-1c is induced by insulin [227] and 
RA [245] in primary hepatocytes, the regulation of Raldh1 expression becomes a 
converge point for a feed-forward mechanism by which VA status regulates lipogenesis 
in the liver. It is reasonable to hypothesize that in hepatocytes of ZL rats, RA derived 
from retinol synergizes with insulin to induce the expression of Srebp-1c mRNA (Figure 
2-6A). The mature SREBP-1c protein supports the expression of RALDH1, which 
promotes the production of RA to maintain the homeostasis of Srebp-1c expression in the 
liver of ZL rats (Figure 2-6A). ZF rats are hyperphagic due to the defect of leptin 
receptor, which leads to the development of obesity, insulin resistance, hyperinsulinemia 
and hyperlipidemia [227, 276]. We have shown that the ZF rat hepatocytes have elevated 
expression levels of Srebp-1c and Fas mRNA [270]. We think that the excessive supply 
of dietary VA caused by hyperphagia and hyperinsulinemia in ZF rats probably work 
together to trigger an elevation of RA production and an induction of Srebp-1c 
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expression in their hepatocytes, respectively. The elevation of the mature SREBP-1c 
protein induces the expression of Raldh1 mRNA, which leads to more RA production, 
and further enhances the expression levels of Srebp-1c and its down-stream lipogenic 
genes. This creates a feed-forward mechanism by which the Srebp-1c expression is 
maintained at a higher level in the liver of ZF rats (Figure 2-6B). Whether the proposed 
feed-forward mechanism is true or not, and what mechanism is responsible for the up-
regulation of Raldh1 expression in the ZF rat liver deserve further investigation.  
In summary, the results shown here suggest that retinol and retinal are 
metabolized into RA and regulate gene expression in rat primary hepatocytes and 
hepatoma cells. In primary rat hepatocytes, the responsible enzymes are most likely 
RDH2 and RALDH1. The expression of Raldh1 mRNA is higher in primary hepatocytes 
from ZF rats than that from ZL rats, which leads to the elevated RALDH1 protein levels 
in the liver of ZF rats. Over-expression of RALDH1 introduces the RAL-mediated 
induction of Srebp-1c in INS-1 cells. Thus, we hypothesize that the change of RA 
production from the over-supply of dietary VA due to the hyperphagia of ZF rats results 
in higher Srebp-1c expression in ZF hepatocytes. The elevated SREBP-1c expression can 
further induce Raldh1 expression to create a feed-forward mechanism that could be one 
of the reasons responsible for the increased lipogenesis in the liver of ZF rats.  
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Figure 2- 1 The mRNA levels of Rdh2, and Raldh1 in (A) freshly isolated and (B) 
cultured primary hepatocytes, and (C) the RALDH1 protein levels in the liver of ad 
libitum ZL and ZF rats.  
(A) and (B) Total RNA was extracted from hepatocytes and subjected to real-time PCR 
analysis. Results were presented as means ± SD of the -∆CT (the CT of 36B4 - the CT of 
indicated transcript) from the indicated different numbers of hepatocyte isolations. * 
P<0.05 for comparing the values of ZL and ZF groups of the indicated transcripts. 
(C) Whole liver tissues lysates were isolated and subjected to immono-blot analysis: (100 
µg/lane) of ZL (lanes 1-4) and ZF (lanes 5-8) rats, and whole cell lysates of INS-1 cells 
infected by Ad-Raldh1 (50 µg, lane 9). The ratio of RALDH1/β-actin were calculated and 
presented as means ± SD of ZL and ZF rats. ** p<0.04 for comparing the ratios of ZL 
rats with that of ZF rats. 
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Figure 2- 2 The expression levels of Cyp26a1 mRNA in response to RA treatment 
(A) over a 24-hour time period, (B) to different dosages of retinol or RAL, and (C) 
to an antagonist of the RAR activation.  
Primary hepatocytes were isolated and pre-treated as described in the Materials and 
Methods. Total RNA was isolated, and subjected to real-time PCR analysis. (A) A 24-
hour time course of Cyp26a1 mRNA expression induced by RA (5 µM) in primary rat 
hepatocytes. * for comparing the vehicle control with the RA groups at the indicated time 
points, and ** and '' for comparing the different time points of vehicle control or RA 
group, all p<0.05. (B) The expression levels of Cyp26a1 mRNA in primary hepatocytes 
treated with increasing concentrations of retinol or retinal for 6 hr. $ for comparing the 
fold induction of retinol group with that of retinal group at the indicated concentrations, c 
> b > a, h > g > f > e > d for comparing the different dosages of retinol or RAL, 
all p<0.05. (C) Inhibition of the RAR activity disrupted the induction of Cyp26a1 by 
retinal treatment. Primary hepatocytes were incubated in medium A without or with 2 µM 
retinal in the absence or presence of increasing concentrations of Ro 41–5253 for 6 hr. i/j 
> l, i'/j' > k' > l' > m' for comparing the different dosages of Ro 41–5253 in the absence or 
presence of RAL, all P<0.05. Results were presented as means ± SD of 3 independent 
hepatocyte isolations. 
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Figure 2- 3 The effects of retinoids on the expression levels of Cyp26a1 mRNA and 
CYP26A1 protein in HL1C cells.  
(A) The dose-dependent induction of Cyp26a1 by ROL, RAL, and RA. HL1C cells were 
treated with ROL, RAL, or RA at the doses of 0, 0.002 µM, 0.02 µM, 0.2 µM, 2 µM, and 
20 µM for 6 hr. a/b < c, d/e < f, g/h < i, j < k/l, m < n/o, a/d/g/j < m, b/e/h < k < n, c/f < 
i/l/o for comparing ROL, retinal and RA at the indicated concentrations, and for 
comparing each ligand at the different dosages, all p<0.05. (B) The expression levels 
of Cyp26a1 mRNA overtime (3, 6, 9, 12, and 24 hr) in HL1C cells treated with 5 µM 
retinal or RA. * or ** for comparing retinal or RA with vehicle control groups at the 
indicated time points, all p<0.05. (C) The expression levels of Cyp26a1 mRNA in HL1C 
cells treated with RAR (TTNPB), RXR (LG268), and LXR (T1317) agonists. HL1C cells 
were treated with 1 µM TTNPB, LG268, and T1317 for 6 hr. Total RNA was extracted 
and subjected to real-time PCR analysis. Data were presented as mean ± SD of 3 
independent treatments. q > r>s, all p<0.05. D. Whole cell lysates (50 µg/sample) of 
HL1C cells treated the vehicle control, 5 µM retinal or RA for 12 (lanes 1–3) and 24 
(lanes 4–6) hr were separated in 8% SDS PAGE gels, and transferred to the PVDF 
membranes.  
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Figure 2- 4 The Srebp-1c mRNA levels in INS-1 cells treated with retinoids or 
ligands.  
(A) 834/40 INS-1 cells were treated with increasing concentrations of retinal or RA for 6 
hr. (B) 834/40 cells were treated with 2 µM of retinal or RA for indicated 
time. (C) 833/15 cells were treated with 1 µM of specific ligands of RXR (LG268), RAR 
(TTNPB) or in combination. Total RNA was extracted from INS-1 cells and subjected to 
real-time PCR analysis. Results were presented as means ± SD of fold inductions. c > b > 
a for comparing the different dosages of RA-treated groups, and e > d > f for comparing 
control with LG 268 in the absence or presence of TTNPB. * for comparing retinal with 
RA groups at the indicated dosages, and ** for comparing RA with retinal or vehicle 
control groups at the indicated time points, n = 3, all P<0.05. 
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Figure 2- 5 The over-expression of RALDH1 resulted in the RAL-mediated 
induction of Srebp-1c in 833/15 INS-1 cells.  
(A) The adenovirus-mediated Raldh1 mRNA expression. (B) Immuno-blot of the over-
expression of RALDH1 protein in INS-1 cells: whole cell lysates (50 µg/sample) of the 
control cells (lane 1), cells infected by the indicated pfu of Ad-β-gal (lane 2), and Ad-
Raldh1 (lanes 3–5). (C) Retinal only induced Srebp-1c expression in cells over-
expressing RALDH1, but not β-gal. D. RA induced Srebp-1c expression in cells over-
expressing either β-gal or RALDH1. Results were presented as means ± SD of fold 
inductions. * for comparing the different dosages of retinal in cells infected by Ad-
Raldh1, n = 3, all p<0.05. 
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Figure 2- 6 The hypothesized role of the RA production in the feed-forward 
induction of the expression of Srebp-1c and its downstream lipogenic genes in the 
liver of ZL (A) and ZF (B) rats.  
(A) In ZL rats, the hepatic expression of Srebp-1c is controlled by the RA production and 
insulin stimulation. The SREBP-1c also regulates RA production via the induction 
of Raldh1 expression until a homeostasis is reached. (B) The hyperphagia of ZF rats due 
to the leptin receptor deficiency causes the over-supply of dietary VA, and 
hyperinsulinemia. The possible elevation of RA production in combination with insulin 
stimulation leads to higher expression of hepatic Srebp-1c in ZF rats, which disrupts the 
homeostasis. The expression of Raldh1 mRNA is further induced by SREBP-1c. 
Therefore, the hepatic expression of Srebp-1c in ZF rats is maintained at a higher level 
than that in ZL rats. The consequence is the elevated hepatic lipogenesis in ZF rats. The 
up arrows next to the texts indicate induction. The intensified weight of the lines 
indicates the induction of that part of the pathway. The question marks indicate the steps 
remained to be confirmed in this hypothesis. 
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Chapter Three 
Effects of vitamin A status on the regulation of hepatic genes in the liver of Zucker 
lean rats during the normal cycle of fasting and refeeding 
1. Introduction 
The high obesity prevalence indicates the future increase of patients with 
metabolic diseases such as type 2 diabetes mellitus (T2DM) [247]. This epidemic has 
become a public health concern [248]. The interactions of genetic and 
environmental/nutritional factors contribute to the development of obesity and its 
associated metabolic diseases. Generally, profound changes of glucose and lipid 
metabolism are often associated with the development of metabolic diseases. However, 
despite the obvious link between overnutrition and the development of metabolic 
diseases, the roles of individual micronutrients have not been elucidated.  
The liver is essential for metabolic homeostasis, which is partially attributed to 
the regulation of the expression levels of hepatic genes for glucose and lipid metabolism 
in response to nutritional and hormonal stimuli [253]. As an anabolic hormone, insulin 
regulates the expression of a variety of hepatic genes involved in glycolysis, 
glycogenesis, gluconeogenesis, and lipogenesis [177]. These regulations contribute to the 
transition of catabolic and anabolic physiological states such as the cycle of fasting and 
refeeding, respectively. To control the glucose and lipid homeostatis, insulin induced 
glycolysis and lipogenesis, and suppresses gluconeogenesis in hepatocytes [277]. For 
instance, to control the hepatic glucose metabolism, insulin induces the expression of 
glucokinase gene (Gck) [178], the first enzyme of hepatic glycolysis, and suppresses the 
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expression of cytosolic form of phosphoenolpyruvate carboxykinase gene (Pck1) and 
glucose 6-phosphatase catalytic subunit (G6pc), the enzymes involved in the first and last 
steps of gluconeogenesis, respectively [179]. To regulate the hepatic lipid metabolism, 
insulin increases the expression level of sterol regulatory element-binding protein 1c 
(Srebp-1c), a family member of SREBPs that regulate the hepatic cholesterol and fatty 
acid biosynthesis [180], which in turn induces the expression of lipogenic genes, such as 
fatty acid synthase gene (Fas) [181]. The hepatic expression levels of all aforementioned 
genes are regulated in the cycles of fasting and refeeding, and have been considered to be 
part of the insulin’s actions to modulate the transition of the body’s metabolic states. 
How insulin signals are integrated with nutritional signals in transitions of physiological 
states is still an open question. 
As an essential micronutrient, vitamin A (VA, retinol) plays crucial roles in the 
general health of an individual, such as vision, tissue differentiation, immunity and etc 
[254]. The majority of the physiological actions of retinol are mediated by its active 
metabolite, retinoic acid (RA), which exists in multiple isomeric forms, such as all-trans 
RA and 9-cis RA [255]. In hepatocytes, retinyl esters are hydrolyzed to retinol, which is 
then either oxidized to RA through a two-step reaction or bound to retinol binding protein 
(RBP) and secreted to the blood circulation for the use of the extrahepatic target tissues 
[14]. The first step of retinol oxidation, from retinol to retinal (also called retinaldehyde), 
is reversible and is catalyzed by retinol dehydrogenases [31]. The second step is 
irreversible and is catalyzed by cytosolic aldehyde dehydrogenases [31]. RA can be 
further modified into more hydrophilic products for disposal by cytochrome P450 family 
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26 (CYP26) enzymes, such as CYP26A1 [70]. RA regulates gene expression mainly 
through the activation of two families of nuclear receptors, RA receptors (RARα, β and γ) 
activated by all-trans RA, and retinoid X receptors (RXRα, β and γ) activated only by 9-
cis RA [256]. In the presence of RA, RAR/RXR heterodimer is activated and recruits 
transcriptional factors to induce the expression of its target genes [278, 279]. Other 
nuclear receptors have been indicated to play a role in mediating the RA signaling [127].  
We have shown recently that that retinoids synergize with insulin to induce the 
expression of Gck [240] and Srebp-1c [245] and attenuate insulin-suppressed Pck1 
expression [243] in primary rat hepatocytes. In addition, the expression levels of Raldh1 
mRNA and RALDH1 protein are elevated in the liver of Zucker fatty (ZF) rats [280]. 
RALDH1 is the main enzyme responsible for the conversion of retinal to RA in the liver 
[51]. Overexpression of RALDH1 introduced retinal-mediated Srebp-1c expression in 
INS-1 cells, indicating the role of the elevated RALDH1 expression in the increased 
lipogenesis in the liver of ZF rats [280]. We hypothesize that the dynamic catabolism of 
VA may contribute to the regulation of the expression of hepatic genes for glucose and 
fatty acid metabolism in response to physiological conditions, such as the cycle of fasting 
and refeeding. 
Here, we report that VA status altered the regulation of plasma glucose and TG 
levels in response to the fasting and refeeding cycle. The products of VA catabolism may 
modulate the expression of hepatic genes for glucose and lipid metabolism during this 
cycle. Cellular RA pool, either from the diet or hepatic VA stores, contributes to the 
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regulation of the expression of insulin-mediated genes, Gck, Pck1, and Srebp-1c, in the 
liver of rats. 
 
2. Materials and Methods 
2.1. Reagents  
Plasma concentrations of glucose, triacylglycerol (TG), and cholesterol were 
determined using kits from Stanbio Laboratory (Boerne, TX). Insulin and leptin RIA kits 
were purchased from Millipore Corporation (Billerica, MA). Reagents for cDNA 
synthesis and real-time PCR were obtained from Applied Biosystems (Foster city, CA).  
Antibodies to acetyl-CoA carboxylase (ACC) (Cat #3676, Cell Signaling 
Technology, Danvers, MA), fatty acid synthase (FAS) (Cat #3180s, Cell Signaling 
Technology, Danvers, MA), ATP citrate lyase (ACL) (Cat #4332s, Cell Signaling 
Technology, Danvers, MA), cytosol form of phosphoenolpyruvate carboxykinase 
(PEPCK-C) (#10004943, Cayman Chemical, Ann Arbor, MI), glucokinase (GK) (sc-
7908, Santa Cruz Biotechnology, Inc., Dallas, TX), and β-Actin (Cat #4970s, Cell 
Signaling Technology, Danvers, MA) were obtained from the perspective vendors as 
indicated, and used according to the protocols provided by the manufacturers.  
2.2. Animals and dietary manipulations 
Male Zucker lean (ZL, wild type and heterozygous) and fatty (ZF) rats were bred 
in the Department of Nutrition at the University of Tennessee at Knoxville. Zucker rats at 
weaning (3 weeks old) were fed a VA sufficient (VAS, #5755, TestDiet) or an isocaloric 
VA deficient (VAD, #5822, TestDiet) diet. Both diets contain the same amount of 
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calories and other nutrients except for VA. The fasting and refeeding experiments were 
implemented when the rats fed the VAD diet stopped gaining body mass (BM). This is 
the most repeatable sign of VA deficiency observed by McCollum and Davis originally 
[281].  
For the dietary manipulation during the cycle of fasting and refeeding, rats were 
divided into four groups upon the development of VA deficiency in the VAD rats. The 
VAS or VAD rats were respectively fed ad libitum (VAS-AD or VAD-AD), fasted for 48  
(VAS-Fasted or VAD-Fasted), or fasted for 48 hr and then refed either a VAS (VAS-
Refed-VAS or VAD-Refed-VAS) or a VAD (VAS-Refed-VAD or VAD-Refed-VAD) 
diet for 6 hr.  At the end of the dietary manipulations, the plasma and tissue samples of 
these animals were collected and subjected to further analysis. BM and tail tip blood 
glucose level were recorded during the fasting and refeeding cycle. Whole blood glucose 
level from the tail tip was measured using OneTouch® UltraMini® Blood Glucose Meter 
(LifeScan, Inc., Milpitas, CA). All procedures were approved by the Institutional Animal 
Care and Use Committee at the University of Tennessee at Knoxville (Protocol numbers 
1256 and 1899). 
2.3. Indirect calorimetry  
To measure the indirect calorimetry, ZL rats were housed individually in 
metabolic cages of Comprehensive Lab Animal Monitoring System (CLAMS, Columbus 
Instruments, Columbus, OH 43204). The system was turned on at least 6 h before use to 
warm up and then it was calibrated using the reference gas (0.4910 % CO2 and 20.50% 
O2 balanced with N2) from Airgas Mid America (St. Louis, MO). During calibration, the 
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percentage of CO2 was adjusted to 0.50% and the percentage of O2 was adjusted to 
20.50%. The BM of each rat was measured before they were placed into the system. The 
data recording of the CLAMS system generally started at 2 pm and stopped at 4 pm the 
next day to get at least 24-hour data that covered 12-hour light and 12-hour dark phases. 
Calorimetric measurements were conducted weekly from the 1st week when the weaning 
rats started to receive a VAS or a VAD diet to the 6th week when animals showed signs 
of VA deficiency. In the CLAMS system, the rats had free access to water and their 
perspective diets ad libitum. Respiratory exchange ratio (RER) and accumulated heat 
production were calculated by the system based on the following formulas. 
RER = VCO2/VO2 
Heat = CV × VO2, CV (calorific value) = 3.815 + 1.232 × RER 
2.4. Plasma analysis 
Accumulated venous blood was collected using the vacuum blood collection tube 
with K3 EDTA coated on the wall (BD, Franklin Lakes, NJ) to block coagulation and 
placed on ice before further processing. Whole blood samples were centrifuged at 3,000× 
rpm for 30 min at 4ºC shortly after they were collected. The supernatant (plasma) was 
transferred to a new tube and stored at -80ºC for later use. The liver was collected after 
the accumulated venous blood was drained up. Liver weight was recorded before frozen 
in liquid nitrogen. The pads of epididymal white adipose tissue (WAT) were removed 
carefully from both sides and were weighed before frozen. All the samples were stored in 
-80ºC freezer for further analysis. 
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Plasma glucose, TG, and cholesterol levels were respectively measured using the 
commercial kits Glucose Standard (Ref #1072-030), Triglycerides Standard (Ref #2103-
030), and Cholesterol Standard (Ref #1012-030) from Stanbio Laboratory (Boerne, TX) 
following the manufacture’s manual. Plasma insulin and leptin concentrations were 
determined with the Insulin RIA kit (Cat #RI-13K) and Leptin RIA kit (Cat #RL-83K) 
from Millipore Corporation according to the manufacture’s manual, respectively. 
2.5. RNA extraction and Quantitative Real-Time PCR  
Total RNA was extracted from about 100 mg liver sample using 1 ml of RNA 
STAT 60 reagent (TEL-TEST, Inc., Friendswood, TX) according to the manufacture’s 
manual. The contaminated DNA was purified and synthesized to cDNA as described 
previously [280]. The real-time PCR primer sequences for detecting insulin receptor 
(Insr) [244], insulin-like growth factor-binding protein 1 (Igfbp1) [243], Gck [282], Pck1 
[265], Srebp-1c [240], and Fas [245] have been reported previously. The gene expression 
level was normalized to that of invariable control gene, 36B4. -∆CT values were obtained 
by subtracting the CT value of 36B4 (an invariable control gene) from the CT values of 
the indicated genes. It indicates difference between the expression levels of 36B4 and 
enzymes. 
2.6. Protein extraction and immuno-blot  
About 100 mg liver tissue was homogenized using a tissue homogenizer (Tissue 
Master 240, OMNI International, Kennesaw, GA) within 1 ml of tissue lysis buffer (1% 
Triton X-100, 10% glycerol, 1% IGEPAL CA-630, 50 mM Hepes, 100 mM NaF, 10 mM 
EDTA, 1 mM sodium molybdate, 1 mM sodium β-glycerophsphate, 5 mM sodium 
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orthovanadate, 1.9 mg/ml aprotinin, 5 µg/ml leupeptin, 1 mM benzamide, 2.5 mM PMSF, 
pH 8.0). The total liver lysates were placed on ice for at least 20 min before they were 
subjected to centrifugation at 13,000× rpm for 20 min. The protein concentration of the 
supernatant was determined using PIERCE BCA protein assay kit (Rockford, IL). 
Proteins (50 µg/lane) in whole tissue lysates were separated on an 8% or 10% SDS-
PAGE gel, transferred to a BIO-RAD Immuno-Blot PVDF membrane (Hercules, CA), 
and detected with primary antibody to ATP citrate lyase (ACL), acetyl-CoA carboxylase 
(ACC), FAS, PEPCK-C, GK, or β-Actin according to the protocols provided by the 
manufacturers. Bound primary antibodies were visualized by chemiluminescence (ECL 
Western Blotting Substrate, Thermo Scientific) using a 1:2,000 dilution of goat anti-
rabbit IgG (#7074P2, Cell signaling Technology) conjugated to horseradish peroxidase. 
Membranes were exposed to X-ray films (Phenix Research Products, Candler, NC) for 
protein band visualization. The films were scanned using an HP Scanjet 3970 (Palo Alto, 
CA 94304) and stored as Tagged Image File Format (TIFF). The ImageJ Software 
(http://rsbweb.nih.gov/ij/) was used to determine the densitometry of the protein bands. 
The ratio of the densities of the detected protein and β-actin in the same sample were 
calculated and used for quantification.  
2.7. Statistics    
Data are presented as means ± SEM. The number represents the plasma or liver 
samples from different animals. Levene’s test was used to determined homogeneity of 
variance among groups using SPSS 21.0 statistical software and where necessary natural 
log transformation was performed before analysis. An independent-samples t-test was 
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used to compare two conditions. Multiple comparisons were analyzed by one-way 
ANOVA using Least Significant Different (LSD) when equal variance was assumed, or 
Games-Howell test and nonparametric test Mann-Whitney U when equal variance was 
not assumed. Differences were considered statistically significant at P < 0.05. 
 
3. Results 
3.1. VA status affects RER in ZL rats 
Figure 3-1A shows that ZL rats fed a VAS diet started to have higher percentage 
gain of BM than those fed a VAD diet did at week 4. The gain of BM in VAD rats 
stopped at week 6, whereas VAS rats continued to gain BM throughout the experimental 
period These results demonstrated the role of VA in the somatic growth of rats and 
confirmed our previous observations [244]. 
In order to determine the effects of VA status on metabolism, we measured RER 
and accumulated heat production of the rats weekly for 6 weeks. As shown in Figure 3-
1B and C, during week 1-3, the RERs of rats fed the VAD diet in both light and dark 
phases were not different from that of the rats fed the VAS diet except for the dark phase 
RER at the end of week 3. The RER values of this period of time were at around 0.85. 
Starting from the end of week 4, the RER values of the rats fed the VAS diet in both light 
and dark phases elevated toward 1.0, while those fed the VAD diet remained at around 
0.85. Compared to the values of light phase RER that were in the range of 0.8-0.95, the 
values of dark phase RER were slightly higher and in the range of 0.85-1.0. The 
accumulated heat productions of the rats fed the VAS diet during both light (Figure 3-1D) 
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and dark phases (Figure 3-1E) were greater than that fed the VAD diet at week 5 and 6. 
However, after normalized to BM, the adjusted accumulated heat productions of VAS 
rats were not different from those of VAD rats during the 6-week time period (data not 
shown), demonstrating the consequences of the reduced BM of the rats fed the VAD diet. 
3.2. The effects of VA status on the body compositions of ZL rats in the cycles of 
fasting and refeeding 
To determine the roles of the dynamic VA catabolism in the modulation of the 
expression levels of genes for glucose and lipid metabolism in the liver, the VAS or VAD 
rats were subjected to the cycle of fasting and refeeding. The ratios of the liver to BM 
(liver/BM) and the epididymal WAT to BM (WAT/BM) were calculated to determine the 
effects of VA status on the body compositions of VAS or VAD ZL rats in the cycle. As 
shown in Figure 3-2A, the liver/BM ratio of VAS rats was not different from that of 
VAD rats. On the other hand, the WAT/BM ratio of VAS-AD rats was significantly 
higher than that of VAD rats (Figure 3-2B). All these data demonstrate that VA status 
does not affect liver/BM ratio, but affects WAT/BM ratio, confirming our previous 
published results [244]. 
3.3. VA status affects plasma levels of glucose and TG of the ZL rats in the cycle 
of fasting and refeeding  
To investigate the effects of VA status on glucose and lipid metabolism, we 
compared the plasma levels of glucose, TG, and cholesterol of those rats in the fasting 
and refeeding cycle. Figure 3-2C shows that the plasma glucose levels of VAD-Refed-
VAS and VAD-Refed-VAD rats were respectively lower than that of VAS-Refed-VAS 
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and VAS-Refed-VAD rats, demonstrating that VA deficiency results in a reduction in 
plasma glucose level. Compared to that of VAS-AD rats, the glucose levels of VAS rats 
(white bars) decreased after fasting (VAS-Fasted) and increased upon refeeding of either 
a VAS or VAD diet (VAS-Refed-VAS or VAS-Refed-VAD) (Figure 3-2C). In the 
contrast, the glucose levels of VAD rats did not return upon refeeding of a VAD diet 
(VAD-Refed-VAD) (Figure 3-2C).  
The plasma TG levels of VAD-Refed-VAS and VAD-Refed-VAD rats were 
respectively lower than that of VAS-Refed-VAS and VAS-Refed-VAD rats (Figure 3-
2D). Compared to that of VAS rats fed ad libitum (VAS-AD), the plasma TG levels of 
VAS rats reduced after fasting (VAS-Fasted) and elevated upon refeeding of either a 
VAS (VAS-Refed-VAS) or a VAD diet (VAS-Refed-VAD). The plasma TG levels of 
VAD rats elevated upon refeeding in those rats fed a VAS diet (VAD-Refed-VAS) but 
not in those fed a VAD diet (VAD-Refed-VAD rats). These results reveal that VA status 
affects the plasma glucose and TG levels in response to the fasting and refeeding cycle, a 
normal physiological phenomenon. 
We also measured the plasma levels of cholesterol among those rats, but no 
significant difference was observed between VAS rats and VAD rats during the fasting 
and refeeding cycle (data not shown). 
3.4. VA status impacts the responses of plasma insulin and leptin levels to the 
cycle of fasting and refeeding 
Figure 3-2E shows that the plasma insulin levels of VAD-AD, VAD-Refed-VAS 
and VAD-Refed-VAD rats were significantly lower than that of VAS-AD, VAS-Refed-
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VAS and VAS-Refed-VAD rats, respectively, demonstrating that VA deficiency reduces 
plasma insulin levels as we have shown previously [244]. The plasma insulin levels of 
VAS rats decreased after fasting (VAS-Fasted) and increased when these animals were 
refed either a VAS (VAS-Refed-VAS) or a VAD diet  (VAS-Refed-VAD) as compared 
to that of VAS rats fed ad libitum (VAS-AD rats) (white columns). The plasma insulin 
levels of VAD rats elevated upon refeeding of a VAS diet (VAD-Refed-VAS) rats but 
not a VAD diet (Figure 3-2E). These results indicate that the dietary VA may directly 
affects plasma insulin levels in VAD rats.  
Figure 3-2F shows that compared to that of VAS-AD rats, the leptin levels of 
VAS rats decreased after fasting (VAS-Fasted) and increased upon refeeding (VAS-
Refed-VAS and VAS-Refed-VAD). However, the leptin levels of VAD rats did not 
change significantly throughout the cycle (grey columns), probably due to the reduction 
of body fat mass. These results indicate that VA status may affect the plasma leptin levels 
via the control of adiposity in rats, and the dietary VA does not affect the plasma leptin 
level in VAD rats. 
3.5. Dynamic catabolism of VA affects the responses of the mRNA expression 
levels of hepatic genes for glucose and lipid metabolism to the cycle of fasting 
and refeeding  
To confirm whether the dynamic VA catabolism in the liver contributes to the 
regulation of the hepatic glucose and fatty acid metabolism, we compared the hepatic 
mRNA levels of Insr, Igfbp1, Gck, Pck1, Srebp-1c, and Fas in rats during the cycle of 
fasting and refeeding. Figure 3-3A shows that the hepatic expression levels of Insr of 
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VAD rats were not different from that of VAS rats in all feeding groups. In addition, the 
cycle of fasting and refeeding did not cause any change in the hepatic Insr mRNA levels 
of both VAD and VAS rats. The hepatic expression levels of Igfbp1 were elevated in all 
VAD groups respectively in comparison to that in VAS groups (Figure 3-3B). Among the 
VAS groups, the hepatic Igfbp1 mRNA levels of VAS-Fasted rats were similar to that of 
VAS-AD rats. However, the Igfbp1 mRNA levels were reduced upon refeeding of a VAS 
(VAS-Refed-VAS), and further decreased after refeeding of a VAD diet (VAS-Refed-
VAD). On the other hand, the hepatic expression levels of Igfbp1 of VAD groups 
remained high and unchanged throughout the cycle. 
The hepatic of Gck mRNA levels of VAD-AD and VAD-Refed-VAD rats were 
significantly lower than that of VAS-AD and VAS-Refed-VAD rats, respectively (Figure 
3-3C). As compared with that of VAS-AD rats, the hepatic expression levels of Gck 
dropped after fasting (VAS-Fasted) and restored after refeeding of either a VAS (VAS-
Refed-VAS) or a VAD (VAS-Refed-VAD) diet. On the other hand, fasting did not 
significantly reduce the hepatic expression levels of Gck of VAD rats (VAD-Fasted) in 
comparison to that of the VAD rats fed ad libitum (VAD-AD). However, refeeding of a 
VAS diet (VAD-Refed-VAS) but not a VAD diet (VAD-Refed-VAD) dramatically 
induced the hepatic expression levels of Gck, indicating that the catabolism of dietary VA 
contributes to the induction of hepatic Gck expression in the cycle of fasting and 
refeeding.  
The hepatic expression levels of Pck1 of VAS-Refed-VAD rats were significantly 
lower than that of VAD-Refed-VAD rats (Figure 3-3D). Compared to that of VAS-AD 
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rats, the hepatic expression levels of Pck1 was reduced by refeeding of either a VAS diet 
(VAS-Refed-VAS) or a VAD diet (VAS-Refed-VAD), which may be caused by the 
suppressive effect of the elevated plasma insulin. The hepatic Pck1 mRNA levels of 
VAD-Refed-VAS rats were slightly lower than that of VAD-Refed-VAD rats probably 
due to the slightly increase in insulin level after refeeding of the VAS diet to the rats 
(Figure 3-2E). These results demonstrate that VA catabolism contributes to the regulation 
of the expression of Gck and Pck1, the representative genes for the hepatic glucose 
metabolism. 
Srebp-1c and Fas are representative genes of the hepatic lipid metabolism. As 
shown in Figure 3-3E, the hepatic expression levels of Srebp-1c of VAD-AD and VAD-
Refed-VAD rats were respectively lower than that of VAS-AD and VAS-Refed-VAD 
rats. Compared to that of VAS-AD rats, the expression levels of Srebp-1c were decreased 
after fasting (VAS-Fasted) and restored upon refeeding of either a VAS (VAS-Refed-
VAS) or a VAD diet (VAS-Refed-VAD). Among the VAD groups, compared to that of 
VAD-AD rats, the hepatic expression levels of Srebp-1c were not significantly decreased 
after fasting (VAD-Fasted) but decreased upon refeeding of a VAD diet (VAD-Refed-
VAS) (grey columns). This result indicates that the catabolism of the dietary VA 
contributes to the induction of Srebp-1c in VAD-Refed-VAS rats. Among the VAS rats, 
the hepatic expression levels of Fas were dramatically reduced after fasting (VAS-
Fasted) and restored upon refeeding of either a VAS diet (VAS-Refed-VAS) or a VAD 
diet (VAS-Refed-VAD) in comparison to that of VAS-AD rats (Figure 3-3F). 
Interestingly, although the hepatic expression levels of Fas in VAD-Fasted rats dropped 
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after fasting, it was still higher than that of VAS-Fasted rats, which deserves further 
investigation. 
3.6. Dynamic catabolism of VA affects the responses of the protein levels of 
hepatic genes for glucose and lipid metabolism to the cycle of fasting and 
refeeding  
To confirm that the changes of mRNA level reflect the changes of protein level in 
the same liver samples, we analyzed the hepatic expression levels of ACL, ACC, FAS, 
PEPCK-C, and GK proteins using immune-blot. The comparison was conducted in two 
ways. The first one was designed to compare the changes of the hepatic protein levels of 
the rats with the same VA status in response to the cycle of fasting and refeeding (Figure 
3-4). The second one was designed to compare the protein levels between the VAD and 
VAS groups (Figure 3-5).   
As shown in Figure 3-4A, the expression levels of ACL, ACC, FAS, and GK 
proteins in the liver of VAS rats dropped after fasting (VAS-Fasted) and slightly restored 
upon refeeding of a VAS diet (VAS-Refed-VAS) in comparison to that of VAS-AD rats 
(Figure 3-4A). But the protein levels of those refed a VAD diet had not been restored 
probably due to that the time when we collected the protein samples, 6-hour refeeding, 
was too early to see the expression at the protein level. The hepatic expression levels of 
PEPCK-C protein of VAS rats were not changed throughout the feeding cycle. As shown 
in Figure 3-4B, the feeding cycle only influenced the expression levels of GK, the 
changes of which were consistent with that of the Gck mRNA levels.  
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Next, we compared the protein levels between VAS rats and VAD rats. In 
comparison to that in the VAS-AD rats, we observed reductions in the hepatic expression 
levels of ACL and GK in the VAD-AD rats (Figure 3-5A). We also observed decreased 
expression levels of ACL and GK in the VAD-Fasted rats as compared to that in the 
VAS-Fasted rats, (Figure 3-5A). The expression levels of FAS of the VAD-Refed-VAS 
rats were lower than that of the VAS-Refed-VAS rats (Figure 3-5B), while the protein 
levels of ACL, FAS, and GK of the VAD-Refed-VAD rats were lower than that of the 
VAS-Refed-VAD rats (Figure 3-5B).  
 
4. Discussion 
Here, we demonstrate that VA status and its dynamic catabolism contribute to the 
regulation of macronutrient metabolism in ZL rats. The RER results obtained from the 
indirect calorimetry demonstrate that the VAS ZL rats are mainly in the anabolic state as 
evidenced by their elevated RER values towards 1.0 after week 4. This indicates that 
VAS rats used carbohydrate as the primary energy source and synthesized fatty acids. On 
the contrary, the RER values of rats fed the VAD diet did not rise, and remained at about 
0.85, which was lower than that of VAS rats after week 4. This suggests that the VAD ZL 
rats used a mixture of carbohydrate and fatty acids as the energy source, and the fatty 
acid synthesis in the VAD rats was low. It is worth to note that the percentage gain of 
BM of VAD ZL rats was reduced at week 4 as well, indicating the development of VA 
deficiency. The RER data indicate that VA status plays a role in the regulation of the 
carbohydrate and fatty acid metabolism, and in turn, the anabolic status in rats. The lower 
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RER value of VAD rats suggests that the anabolic rate of rats seems to require the 
presence of VA. In another word, VA contributes to the maintenance of anabolic state in 
rats.  
The accumulated heat production of VAS rats after week 4 was higher than that of 
VAD rats, which is reasonable because VAS rats had larger body size that may produce 
more heat. After we normalized the heat production to BM (data not shown), the adjusted 
heat production of VAS rats was no longer different from that of VAD rats. We have 
shown previously and in this study that VAD rats have less body fat than VAS rats do. 
This indicates that VAD rats may have relatively higher lean BM to total BM ratio than 
VAS rats have. Theoretically, muscle cells produce more heat than fat cells do. To 
maintain the same adjusted heat production rate, the heat production rate per unit of 
muscle mass of VAD rats might be lower than that of VAS rats. It has been shown that 
RA induces the expression of uncoupling protein 3 in muscle cells [283, 284]. It will be 
interesting to determine the roles of VA status in muscle metabolism and heat production, 
an ongoing project in our lab.  
It has been shown that glucose-stimulated insulin secretion is impaired in islets or 
pancreas isolated from VAD rats, which can be restored after the replenishment of VA 
status in those animals [157]. In our study, we observed that VA deficiency altered the 
normal response of plasma insulin level to the fasting and refeeding cycle, and led to a 
significant reduction of it [244]. The depletion of VA storage may lead to 
hypoinsulinemia in VAD rats, indicating the important role of VA storage in maintaining 
normal plasma insulin levels. The increase in insulin level of VAD-Refed-VAS rats may 
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be attributed to the dynamic usage of the dietary VA. But this increase was not as high as 
that in VAS-Refed-VAS rats, which may suggest that dynamic VA usage or RA 
production from the diet alone is not sufficient to completely restore insulin secretion in 
the current experimental settings. The stored and dietary VA may be integrated into the 
intracellular VA pool to maintain the normal insulin release from pancreatic β-cells.  
It is interesting to note that the response of plasma leptin levels to the fasting and 
refeeding cycle is also affected by VA status. Leptin is secreted from WAT, and its 
circulating level is closely related to fat mass [141] and calorie intake [285]. Normally, 
plasma leptin level falls during fasting and increases upon refeeding [286] as we 
observed in VAS rats. But the response of leptin to the cycle of fasting and refeeding was 
significantly blunted in VAD rats according to our observation. This may be attributed to 
the loss of WAT caused by the VAD status. Indeed, the ratio of WAT/BM of VAD rats 
was significantly lower than that of VAS rats (Figure 3-2B), which may limit the leptin 
produced from WAT in response to refeeding.  
Insulin induces Gck expression [287] and suppresses Pck1 expression [288] in the 
liver, which has been considered a signature event in the cycle of fasting and refeeding. 
Insulin also inhibits the hepatic expression of Igfbp1 that prevents hypoglycemia caused 
by insulin-like growth factor 1 [289]. In our study, the elevated expression level of Igfbp1 
in VAD rats is probably due to the reduction in plasma insulin level. However, it is 
interesting to note that the hepatic expression levels of Igfbp1 of VAS-AD rats were 
similar to that of VAS-Fasted rats. It suggests that the decrease in plasma insulin level of 
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VAS-Fasted rats may not be sufficient to affect the Igfbp1 mRNA levels, indicating the 
involvement of other factors in the control of Igfbp1 expression in ad libitum state. 
 The decrease in Gck mRNA levels of VAD rats seems to be the combined effects 
of decreased insulin levels and VA deficiency. The Gck expression levels of VAD-Refed-
VAS rats were not as low as that of VAD-Refed-VAD rats probably due to the relatively 
higher levels of insulin of VAD-Refed-VAS rats. We have reported that retinoids 
synergize with insulin to induce Gck expression in primary rat hepatocytes [240]. Here, 
the in vivo data also demonstrate that dynamic RA production from diet synergizes with 
insulin to induce Gck expression in VAD-Refed-VAS rats. The expression of GK at the 
protein level is consistent with that at the mRNA level. Thus, RA production, from either 
VA storage or dietary source, modulates the insulin-induced Gck expression in the liver. 
We have reported that retinoids attenuate insulin-mediated suppression of Pck1 in 
primary rat hepatocytes [243]. In the current study, the hepatic expression of Pck1 does 
not seem to be influenced by the RA pool.  
On the other hand, insulin controls hepatic lipogenesis via stimulating the 
expression of Srebp-1c and its downstream targeted gene Fas [180]. VA deficiency led to 
the reduced expression levels of Srebp-1c, which is due to the combined effects of 
decease in insulin levels and RA production. The higher mRNA levels of Srebp-1c in 
VAD-Refed-VAS rats compared to that in VAD-Refed-VAD rats suggest that dynamic 
RA production from diet synergizes with insulin to induce Srebp-1c expression, which is 
consistent with our previous observation in primary rat hepatocytes [245]. The change of 
mRNA levels of Fas was consistent with that of Srebp-1c except for the one after fasting. 
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The expression levels of Fas in VAD-Fasted rats were higher than that of VAS-Fasted 
rats, indicating that factors other than Srebp-1c may regulate Fas expression after 
prolonged fasting. The immune-blotting results of FAS of fasted rats are not consistent to 
that at the mRNA level, suggesting that protein stability may play a role in this 
phenomenon.  
Theoretically, RA is dynamically produced and rapidly turned over inside a cell. 
At any moment, the hepatocyte RA pool may be derived from two sources: one is 
produced directly from dietary VA; the other one is from stored VA in liver stellate cells. 
VAS rats have adequate VA stores in the liver whereas VAD rats should have depleted 
stores of hepatic VA. The rats refed the VAS diet for 6 hr should be able to use RA 
derived from both the stored VA, if they had, and the dietary VA. However, the rats refed 
the VAD diet could only use the stored RA, if they had. Our results obtained from the 
VAD rats indicate that the dietary VA plays an important role in the regulation of the 
hepatic expression of genes involved in glucose and fatty acid homeostasis. After the 
refeeding, the dietary VA is probably channeled immediately to the VA pool in the 
hepatocytes and utilized for RA production. Therefore, dynamic RA production 
contributes to the regulation of hepatic glucose and lipid metabolism in normal 
physiological conditions. 
In summary, we have demonstrated that VA is essential in maintaining the normal 
responses of plasma levels of glucose, TG, insulin, and leptin to the cycle of fasting and 
refeeding. VAD rats had reduced levels of plasma glucose and TG, which is attributed to 
the altered plasma levels of hormones (insulin and leptin) and changes of expression 
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levels of genes involved in hepatic glucose and lipid metabolism. We believe that cellular 
VA pool plays important roles in the modulation of insulin-mediated gene expression in 
the liver. Both sources of the dietary VA and hepatic stored VA contribute to the 
formation of cellular VA pool. Therefore, we conclude that cellular VA, either from the 
dietary or stored source, contributes to the regulation of the expression of genes in 
hepatic glucose and lipid metabolism. 
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Figure 3- 1 Body mass gain ratio and weekly RER and accumulated heat of VAS 
and VAD rats before the fasting and refeeding cycle.  
Body mass gain ratio = (weekly body mass – initial body mass) / initial body weight.  
Body mass of VAS and VAD rats were recorded weekly. Results were represented as 
means ± SEM of 6 independent experiments. VCO2 and VO2 (RER) of VAS and VAD 
rats were measured weekly using the indirect calorimetry system. RER (VCO2/VO2) 
during (B) light and (C) dark and accumulated heat production during (D) light and (E) 
dark were calculated automatically by the system. Results were represented means ± 
SEM of 6 independent experiments. * for comparing the control VAS rats and VAD rats; 
all P<0.05. 
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Figure 3- 2 Ratios of (A) liver/BM and (B) WAT/BM and plasma levels of (C) 
glucose, (D) TG, (E) insulin, and (F) leptin of VAS and VAD rats after the fasting 
and refeeding cycle.  
The ratios of liver/BM and WAT/BM were calculated and compared between VAS and 
VAD rats. Data were represented means ± SEM of 9 independent experiments. * for 
comparing the control VAS rats and VAD rats at the indicated groups; all P<0.05. 
Accumulated venous plasma samples were collected at the end the feeding cycle. Plasma 
glucose, TG, insulin, and leptin levels were measured using the available commercial 
kits. Results were represented means ± SEM of 6 independent experiments. * for 
comparing the control VAS rats and VAD rats at the indicated groups, a>b, a’>b’, d<c<e, 
c’>f’, e’>d’/f’, g<f<h, g’<h’, i>j, all P<0.05. Ad=ad libitum, Fast=fasting, VAS=refed 
VAS, VAD=refed VAD. 
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Figure 3- 3 The expression levels of (A) Insr, (B) Igfbp1, (C) Gck, (D) Pck1, (E) 
Srebp-1c, and (F) Fas of VAS and VAD rats after the fasting and refeeding cycle.  
Liver tissue samples were collected at the end of the feeding cycle. Total RNAs were 
extracted and subjected to real-time PCR analysis. Results were presented as means ± 
SEM of the -∆CT (the CT of 36B4 - the CT of indicated transcript) from 4 independent 
experiments. * for comparing the control VAS rats and VAD rats at the indicated groups, 
a>b>c, d<c<e, a’<b’, f>g, c’>d’, h>i, e’>f’, j>k, g’<h’, all P<0.05. Ad=ad libitum, 
Fast=fasting, VAS=refed VAS, VAD=refed VAD. 
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Figure 3- 4 The immono-blot of ACC, FAS, ACL, PEPCK, and GK in the liver of 
(A) VAS rats and (B) VAD rats after the fasting and refeeding cycle.  
Liver samples were collected at the end of the feeding cycle. Proteins (50 µg/lane) in 
whole cell lysates were isolated and subjected to immono-blot analysis. The ImageJ 
Software was used to determine the densitometry of a protein band. Results were 
presented as means ± SEM of the ratio of the measured protein to β-actin from 3 
independent experiments. a>c>b, d>e, f>h>i>g, j>k, a’<b’, p<0.05. 
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Figure 3- 5 Comparison of the protein levels in (A) ad libitum and fasting states and 
in (B) VAS refeeding and VAD refeeding states. 
Liver samples were collected at the end of the feeding cycle. Proteins (50 µg/lane) in 
whole cell lysates were isolated and subjected to immono-blot analysis. The ImageJ 
Software was used to determine the densitometry of a protein band. * for comparing the 
different ratios of VAS rats and that of VAD rats, all p<0.05. 
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Chapter Four 
Effects of vitamin A status on the regulation of hepatic genes in the liver of STZ-
induced diabetic Zucker lean rats 
1. Introduction 
Metabolic homeostasis is achieved through the coordinative actions of nutritional 
and hormonal signals. Insulin is the most important one as the lack of its action leads to 
the development of diabetes mellitus. Insulin exerts it activities at least in part through 
the regulation of the expression of genes for the hepatic glucose and lipid metabolism. As 
an anabolic hormone, insulin is responsible for the expression of a variety of hepatic 
genes involved in glycolysis, glycogenesis, gluconeogenesis, and lipogenesis [177]. For 
example, to control the hepatic glucose metabolism, insulin is required for the induction 
of glucokinase gene (Gck) [178], the first enzyme of hepatic glycolysis, and suppression 
of cytosolic form of phosphoenolpyruvate carboxykinase gene (Pck1) and glucose 6-
phosphatase catalytic subunit (G6pc), the enzymes involved in the first and last steps of 
gluconeogenesis, respectively [179].  
It has been shown previously that insulin is also required for the hepatic fatty acid 
synthesis in the cycle of fasting and refeeding. The hepatic fatty acid synthesis rises 
sharply and continuously for more than 20 hr after rats were fasted for 48 hr and then 
refed a fat-free diet [290]. The amount and activity of fatty acid synthase (FAS), the 
enzyme responsible for fatty acid synthesis, are increased in normal rats refed a high 
carbohydrate diet after fasting and in diabetic rats after insulin injection [215].  However, 
in insulin-deficient rats, the induction of FAS after refeeding is lost until insulin is 
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injected, demonstrating the essential role of insulin in the induction of FAS activities in a 
refeeding condition [291]. This induction of FAS activity is attributed to the induction of 
its gene (Fas) transcripts [216, 292]. This has been attributed to insulin-induced 
expression of sterol regulatory element-binding protein 1c (Srebp-1c), a family member 
of SREBPs that regulate the hepatic cholesterol and fatty acid biosynthesis [180], which 
in turn induces the expression of lipogenic genes, such as Fas [181].  
Vitamin A (VA, retinol) is an essential micronutrient that plays crucial roles in 
vision, cell differentiation, immunity and etc [254]. The majority of VA’s physiological 
functions are mediated by its active metabolite, retinoic acid (RA). RA exists in multiple 
isomeric forms, such as all-trans RA and 9-cis RA [255]. RA regulates gene expression 
mainly through the activation of two families of nuclear receptors, RA receptors (RARα, 
β and γ) activated by all-trans RA, and retinoid X receptors (RXRα, β and γ) activated 
only by 9-cis RA [256]. RAR/RXR heterodimer, located at RA responsive element 
(RARE) in the promoter region of RA responsive genes, is activated upon binding of RA 
and recruits transcriptional factors to induce the target gene expression [278, 279]. Other 
nuclear receptors have been indicated to play a role in mediating the RA signaling [127].  
Experimental results from our lab have shown that VA status plays a role in the 
regulation of plasma glucose and triacylglycerol (TG) levels, and expression of genes for 
the hepatic glucose and lipid metabolism. Retinoids synergize with insulin to induce Gck 
expression via the activation of RAR/RXR in primary rat hepatocytes [240]. 
Additionally, decreased Gck mRNA levels and activity were observed in the liver of VA-
deficient (VAD) rats as compared to those of VA-sufficient (VAS) rats [240]. Retinoids 
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induce Pck1 expression and attenuate insulin-mediated suppression in primary rat 
hepatocytes [243]. VA deficiency only reduces hepatic Pck1 mRNA levels in Zucker lean 
(ZL) rats but not in Zucker fatty (ZF) rats [244]. Retinoids synergize with insulin to 
induce Srebp-1c expression in primary rat hepatocytes [245]. In addition, the elevated 
expression levels of retinaldehyde dehydrogenase 1 gene (Raldh1) and RALDH1 protein 
in the liver of ZF rats may contribute to the increased lipogenesis in them [280].  
Since both retinoids and insulin work together to regulate the expression of 
several hepatic genes involved in glucose and fatty acid metabolism, the open question is 
whether VA is needed for insulin-regulated hepatic gene expression under 
physiologically relevant conditions, such as type 1 diabetes mellitus (T1DM). 
Streptozotocin (STZ) has been used frequently to induce T1DM in lab animals since it 
was reported to be diabetogenic [293]. STZ enters pancreatic β-cells through glucose 
transporter 2 (GLUT2) [294], causes damages of β-cells [295], and leads to the 
development of hyperglycemia and T1DM [296]. The STZ-induced diabetes is a 
desirable model for us to investigate the roles of retinoids in the modulation of the 
expression of insulin-regulated genes.  
Here, we used STZ to induce T1DM in VAS and VAD ZL rats. The animals with 
T1DM were treated with saline (control), insulin, RA or insulin + RA. The mRNA and 
protein levels of representative insulin responsible genes in the liver of those animals 
were analyzed. We demonstrate here that VA status affects the expression of insulin-
mediated hepatic genes for glucose and fatty acid metabolism in diabetic rats.  
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2. Materials and Methods 
2.1. Reagents  
Plasma glucose, TG, and cholesterol levels kits were obtained from Stanbio 
Laboratory (Boerne, TX). Insulin, leptin, and glucagon RIA kits were purchased from 
Millipore Corporation (Billerica, MA). Reagents for cDNA synthesis and real-time PCR 
were obtained from Applied Biosystems (Foster city, CA). STZ, insulin, and RA were 
obtained from Sigma (St. Louis, MO). STZ was prepared in sodium citrate solution at 
50mM (pH 4.5) freshly before each injection. Insulin was dissolved in in saline and 
stored at 4°C before use. 2.5 mg RA was dissolved in 5 ml PBS with 100 µl ethanol and 
10 µl Tween 80 reaching the final concentration of 0.5 mg/ml and stored at -20°C before 
injection. Antibodies to ATP citrate lyase (ACL, Cat #4332s), acetyl-CoA carboxylase 
(ACC, Cat #3676), FAS (Cat #3180s), and β-Actin (Cat #4970s) were obtained from Cell 
Signaling Technology (Danvers, MA). Antibodies to cytosol form of 
phosphoenolpyruvate carboxykinase (PEPCK-C, #10004943) and glucokinase (GK, sc-
7908) were from Cayman Chemical (Ann Arbor, MI) and Santa Cruz Biotechnology Inc. 
(Dallas, TX), respectively.  
2.2. Animals and treatments of reagents 
Male ZL (wild type and heterozygous) rats at weaning (3 weeks old) were fed a 
VA sufficient (VAS, #5755, TestDiet) or an isocaloric VA deficient (VAD, #5822, 
TestDiet) diet. Both diets contain the same amount of calories and other nutrients except 
for VA. Treatments of STZ and insulin were implemented according to a protocol 
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described by Lakshmanan [291] after rats fed the VAD diet stopped gaining body mass 
(BM) and showed signs of VA deficiency.  
  Rats were fasted for 24 hr, and received a single injection of STZ (65 mg/kg 
BM) via the tail vein. After that, the VAS or VAD diet was provided ad libitum to the 
VAS or VAD rats, respectively. Tail whole blood glucose was measured 24 hr after the 
STZ injection using OneTouch® UltraMini® Blood Glucose Meter (LifeScan, Inc., 
Milpitas, CA) to confirm the successful induction of STZ-induced diabetes (glucose level 
> 250 mg/dL). Then the VAS or VAD rats with STZ-induced diabetes were divided into 
four groups. They were injected with saline (control, 100 µL, intramuscularlly), insulin 
(0.5 IU/100 g BM, intramuscularly), RA (100 µg in PBS, intraperitonealy), or insulin + 
RA (intramuscularly and intraperitonealy, respectively). BM and tail vein blood glucose 
were recorded during the treatment of reagents.  Rats were fed ad libitum for 3-4 hr and 
then euthanized for tissue sample collection. The procedures were approved by the 
Institutional Animal Care and Use Committee at the University of Tennessee at 
Knoxville (Protocol numbers 1256 and 1899). 
2.3. Tissue sample collection and analysis of plasma parameters 
Accumulated venous blood was collected using the vacuum blood collection tube 
with K3 EDTA coated on the wall (BD, Franklin Lakes, NJ) to block the coagulation. 
Whole blood samples were centrifuged at 3,000×rpm for 30 min at 4ºC shortly after they 
were collected and stored on ice. The supernatant (plasma) was transferred to a new tube 
and stored at -80ºC for further analysis. The liver was collected after the accumulated 
venous blood was drained up. Liver weight was recorded before frozen in liquid nitrogen. 
 103 
Epididymal white adipose tissues (WAT) were cut carefully from both sides and were 
weighed before frozen. All samples were stored in -80ºC freezer for further analysis. 
Plasma glucose, TG, and ketone levels were respectively measured using the 
commercial kits Glucose Standard (Ref #1072-030), Triglycerides Standard (Ref #2103-
030), and β-Hydroxybutyrate/TDM Linearity Standard (Ref #2450-604) from Stanbio 
Laboratory (Boerne, TX) following the manufacture’s manual. Plasma insulin, leptin, and 
glucagon concentrations were determined with the Insulin RIA kit (Cat #RI-13K), Leptin 
RIA kit (Cat #RL-83K), and Glucagon RIA kit (Cat #GL-32K) from Millipore 
Corporation (Billerica, MA), respectively. 
2.4. RNA extraction and Quantitative Real-Time PCR  
Total RNA was extracted from about 100 mg liver sample using 1 ml of RNA 
STAT 60 reagent (TEL-TEST, Inc., Friendswood, TX) according to the manufacture’s 
protocol. The contaminated DNA was removed, and cDNA was synthesized as described 
previously [280]. The real-time PCR primer sequences for detecting Cyp26a1 [268], 
G6pc [243], Gck [282], Pck1 [265], Srebp-1c [240], and Fas [245] have been reported 
previously. The gene expression levels were normalized to that of invariable control 
gene, 36B4. Minus ∆CT values were obtained by subtracting the CT value of 36B4 (an 
invariable control gene) from the CT values of the indicated genes. This indicates the 
difference between the expression level of 36B4 and that of the measured transcript. 
2.5. Protein extraction and immuno-blot  
About 100 mg liver tissue was homogenized using a tissue homogenizer (Tissue 
Master 240, OMNI International, Kennesaw, GA) within 1 ml of tissue lysis buffer (1% 
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Triton X-100, 10% glycerol, 1% IGEPAL CA-630, 50 mM Hepes, 100 mM NaF, 10 mM 
EDTA, 1 mM sodium molybdate, 1 mM sodium β-glycerophsphate, 5 mM sodium 
orthovanadate, 1.9 mg/ml aprotinin, 5 µg/ml leupeptin, 1mM benzamide, 2.5 mM PMSF, 
pH 8.0). The total liver lysates were placed on ice for at least 20 min before they were 
subjected to centrifugation at 13,000×rpm for 20 min. The protein concentration in the 
supernatant was determined with PIERCE BCA protein assay kit (Rockford, IL). Proteins 
(50 µg/lane) in whole tissue lysates were separated on an 8% or 10% SDS-PAGE, 
transferred to a BIO-RAD Immuno-Blot PVDF membrane (Hercules, CA) and detected 
with primary antibodies to acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), 
ATP citrate lyase (ACL), cytosol form of phosphoenolpyruvate carboxykinase (PEPCK-
C), glucokinase (GK), CYP26a1 and β-Actin according to the protocols provided by the 
manufacturers. Bound primary antibodies were visualized by chemiluminescence (ECL 
Western Blotting Substrate, Thermo Scientific) using a 1:2,000 dilution of goat anti-
rabbit IgG (#7074P2, Cell signaling Technology) conjugated to horseradish peroxidase. 
Membranes were exposed to X-ray films (Phenix Research Products, Candler, NC) for 
protein band visualization. The films were scanned using an HP Scanjet 3970 (Palo Alto, 
CA 94304) and stored as Tagged Image File Format (TIFF). The ImageJ Software 
(http://rsbweb.nih.gov/ij/) was used to determine the densitometry of the protein bands. 
The ratio of the densities of the detected protein and β-actin in the same sample were 
calculated and used for quantification.  
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2.6. Statistics    
Data are presented as means ± SEM. The number of each group represents the 
total number of different animals received the indicated treatment. SPSS 21.0 statistical 
software (IBM Corporation, Armonk, NY) was used for statistical analysis. Levene’s test 
was used to determine homogeneity of variance among groups and the necessary natural 
log transformation was performed before analysis. An independent-samples t-test was 
used to compare two conditions. Multiple comparisons were analyzed by one-way 
ANOVA using least significant different (LSD) when equal variance was assumed, and 
Games-Howell test and nonparametric test Mann-Whitney U were used when equal 
variance was not assumed. Differences were considered statistically significant at p < 
0.05. 
 
3. Results 
3.1. Effects of VA status on the body compositions of STZ-induced diabetic rats 
To induce VA deficiency, ZL rats were fed on a VAD diet at weaning. BM was 
recorded weekly to monitor the growth of the rats. Figure 4-1A shows that BM of VAD 
rats started to drop in week 5 and 6 compared to that of VAS rats. At the same time, we 
observed early signs of VA deficiency, such as dryness of the cornea, on those rats fed 
the VAD diet. 
The liver/BM ratio and WAT/BM ratio of VAS and VAD rats were compared to 
evaluate the effects of VA status on the body compositions of STZ-induced diabetic rats. 
Figure 4-1B shows that the liver/BM ratios of VAD rats were not different from that of 
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VAS rats. However, the WAT/BM ratios of VAD rats were significantly lower than that 
of VAS rats (Figure 4-1C). These results were consistent with the results in our previous 
studies [244]. 
3.2. Effects of VA status on plasma levels of glucose, TG, and cholesterol in STZ-
induced diabetic rats  
The levels of peripheral tail whole blood glucose were recorded after fasting, STZ 
injection, and the treatment to monitor the changes of blood glucose throughout the 
experimental process. As shown in Table 4-1, a single STZ treatment was sufficient to 
induce the plasma glucose levels to reach more than 400 mg/dL in both VAS and VAD 
rats, indicating the successful development of T1DM. Saline or RA did not cause any 
change of plasma glucose levels. On the other hand, treatments of insulin or insulin + RA 
reduced the levels of tail tip whole blood glucose in both VAS and VAD rats. These 
results indicate that the amount of insulin and the time chosen were enough for us to 
observe the insulin action to lower peripheral whole blood glucose in STZ-induced 
diabetic rats. This setting allowed us to study the effects of insulin and RA on plasma 
levels of parameters and the expression levels of hepatic genes. 
To investigate the effects of VA status on the homeostasis of glucose and lipid in 
diabetic rats, we analyzed the plasma parameters in plasma derived from the inferior vena 
cava. Figure 4-2A shows that the RA treatment alone did not affect the glucose levels of 
both VAS and VAD rats compared to that in the control groups. At the time of tissue 
collection, the accumulated venous plasma glucose levels in the ad libitum VAS rats 
treated with insulin or insulin + RA tended to be lower, but did not reach statistical 
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significance, than the ones treated with saline, suggesting the limitation of one injection 
of insulin to control the blood glucose in ad libitum VAS rats for 3 hr. On the other hand, 
insulin or insulin + RA treatment significantly reduced the glucose levels in VAD rats 
similarly. The results indicate that VA status seems to affect the control of plasma 
glucose in diabetic rats after a single insulin injection [291]. The amount of insulin we 
injected to rats was sufficient to control the plasma glucose levels in VAD rats for more 
than 3 hr, which might not be enough for the VAS rats.  
The plasma levels of TG in VAS diabetic rats treated with RA, insulin, or insulin 
+ RA were comparable to that in the control rats, probably due to the large variation of 
the control group (Figure 4-2B). RA treatment alone did not change the TG levels in 
VAD rats, but insulin treatment significantly decreased the TG levels of VAD rats. 
Treatment of insulin + RA slightly but not significantly reduced the TG levels in VAD 
rats. Thus, plasma levels of TG in diabetic rats are more sensitive to the treatment of 
insulin in the absence of VA.  
The plasma levels of ketone in both VAS and VAD rats were reduced by the 
treatments of insulin or insulin + RA in comparison to that in the control groups (Figure 
4-2C), indicating the effectiveness of insulin treatment.  
3.3. Effects of VA status on plasma levels of plasma insulin, leptin, and glucagon 
in STZ-induced diabetic rats  
Figure 4-2D shows that rats treated with saline (control) or RA had extremely low 
levels of insulin, indicating no endogenous insulin secretion due to the loss of the 
pancreatic β-cells caused by STZ treatment. Treatment of insulin or insulin + RA 
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increased the plasma levels of insulin in both VAS and VAD rats as compared to that in 
the control groups, suggesting the successful injection of insulin to the rats.  
The plasma levels of leptin of VAS rats were not affected by the treatment of RA 
or insulin (Figure 4-2E). However, markedly induction of plasma leptin levels were 
observed in VAD rats treated with RA, insulin, or insulin + RA. Thus, VA status affects 
the response of leptin levels to the indicated treatments in diabetic rats. The plasma leptin 
levels in VAD diabetic rats are more sensitive to the treatment of insulin.  
RA or insulin treatment alone did not affect the plasma levels of glucagon in VAS 
rat compared to the control group, but insulin + RA treatment decreased its levels (Figure 
4-2F). Treatment of RA alone did not change the plasma levels of glucagon of VAD rats. 
However, treatment of insulin or insulin + RA significantly reduced the glucagon levels 
in VAD rats. These results suggest that the plasma levels of glucagon are affected by VA 
status. Insulin treatment decreases its levels in diabetic VAD rats.  
3.4. VA status affects the responses of the expression levels of hepatic genes for 
glucose and lipid metabolism to RA and insulin treatments 
To confirm the successful injection of RA, we compared the hepatic mRNA 
levels of Cyp26a1 after the indicated treatments. As shown in Figure 4-3A, the 
expression levels of Cyp26a1 in rats treated with RA or insulin + RA were higher than 
that in the saline (control) or insulin group, demonstrating that the amount of RA injected 
was sufficient to induce gene expression.  
To investigate the effects of VA status and RA treatment on the expression levels 
of hepatic genes for glucose and fatty acid metabolism, we determined the mRNA levels 
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of Gck, Pck1, and Srebp-1c in the liver of STZ-induced diabetic rats after the indicated 
treatments. Figure 4-3B shows that the hepatic expression levels of Gck in VAS rats were 
induced after the treatment of insulin or insulin + RA as compared to that in the control 
group. The Gck mRNA levels in VAD rats were increased upon the treatment of RA and 
its levels were further increased by the treatment of insulin and even further elevated by 
the treatment of insulin + RA. These results demonstrate that VA status affects the 
expression levels of Gck after the treatment of insulin. VAD rats without any storage of 
VA are more sensitive to the RA treatment. In VAD rats, RA alone is sufficient to induce 
the hepatic expression of Gck, and RA also synergizes with insulin to further induce its 
expression.  
As shown in Figure 4-3C, the hepatic expression levels of Pck1 in VAS rats were 
reduced after the injection of insulin or insulin + RA in comparison to that in the control 
group. The mRNA levels of Pck1 in VAD rats were also decreased after the treatment of 
insulin or insulin + RA, and the reductions (∆ Ct of 3.94 and 4.19) were more significant 
than that in the VAS rats (∆ Ct of 2.63 and 3.95). Thus, VA status may also affect the 
expression levels of Pck1 after the treatment of reagents. The Pck1 expression levels in 
VAD diabetic rats are more sensitive to the treatment of insulin or insulin + RA, 
suggesting that the stored VA and its metabolism may play a role in the attenuation of 
insulin-mediated suppression of Pck1 expression.  
Figure 4-3D shows that the treatment of insulin or insulin + RA induced the 
mRNA levels of Srebp-1c in VAD rats as compared to the control group, but not that in 
VAS rats probably due to the big variation in the control group of VAS rats. This 
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demonstrates that VA status contributes to insulin-mediated induction of Srebp-1c 
expression. The Srebp-1c mRNA levels of VAD diabetic rats are more likely to be 
affected by the treatment of insulin.  
We also compared the expression of CYP26A1, ACC, FAS, PEPCK, and GK at 
the protein level. ACC and FAS are the enzymes for the productions of malonyl-CoA and 
palmitate, which are essential for de novo fatty acid biosynthesis. Figure 4-4 shows that 
treatment of insulin + RA induced the expression of CYP26A1 as compared to that of the 
control groups. As shown in Figure 4-5A, the expression levels of PEPCK in VAS rats 
were significantly reduced upon the treatment of RA, insulin, or insulin + RA as 
compared to that in the control group. The 3-hour treatment of insulin or RA did not 
influence the expression of ACC and FAS in VAS rats. The insulin-mediated expression 
of GK in VAS rats is increased by the treatment of insulin + RA. In Figure 4-5B, 
treatment of insulin or insulin + RA induced the protein levels of ACC and FAS but 
dramatically suppressed the expression of PEPCK in VAD rats. Treatment of insulin 
induced GK expression and insulin + RA treatment further increased its protein level, 
which was consistent to the real-time PCR result. 
 
4. Discussion 
Stored VA and dynamic RA production may be integrated into the intracellular 
VA pool to maintain the normal insulin release from pancreatic β-cells. In this study, all 
the ZL rats were induced to develop T1DM via injection of STZ. They had no 
endogenous insulin secretion. The STZ-induced diabetic rats treated with RA had 
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exogenous RA that contributes to the intracellular RA pool but did not have endogenous 
insulin secretion. This is a desirable model to study the roles of VA in the regulation of 
hepatic expression of genes for glucose and lipid metabolism. Rats treated with insulin 
had exogenous insulin supply to regulate insulin-mediated gene expression. Rats treated 
with insulin + RA had both insulin and RA, which is an ideal model to study the 
combined effects of insulin and RA on hepatic gene expression. Rats were fed with either 
a VAS diet or a VAD diet to investigate whether VA status or stored VA affects the 
hepatic gene expression and plasma levels of nutrients and hormones in response to the 
treatments of RA and insulin.  
The plasma results had demonstrated that injection of insulin or insulin + RA 
successfully increased the plasma insulin levels (Figure 4-2D). The results of real-time 
PCR had proven that the amount of RA injected was sufficient to induce gene expression 
at the mRNA level (Figure 4-3A). The plasma data show that VA status affects the 
plasma levels of nutrients and hormones in response to RA and insulin treatments. It 
seems that VAD rats were more sensitive to these treatments. We did observe that tail tip 
whole blood glucose levels in both VAS and VAD rats decreased after treatments of 
insulin or insulin + RA as shown in Table 4-1. However, the accumulated venous plasma 
glucose levels in VAS rats were not reduced significantly by insulin or insulin + RA 
treatment. It seems that the insulin responses in the liver and peripheral tissues are not 
equal or nonconcurrent in VAS rats. This phenomenon could be attributed to the higher 
amount of insulin needed to control the hepatic gluconeogenesis or more less amount of 
insulin required for the peripheral glucose disposal. Given the data obtained from VAD 
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rats, it indicates that VA status affects this phenomenon. This deserves further study 
regarding the efficient amount of insulin for reducing accumulated venous plasma 
glucose levels.  
The clearance of plasma TG-rich lipoprotein particles, such as very low-density 
lipoproteins (VLDL), is dependent on lipoprotein lipase (LPL) the activity of which is 
mainly regulated by insulin [297]. Insulin deficiency is associated with low adipocyte 
LPL activity in diabetic rats, which is increased by insulin treatment [298, 299]. In the 
presence of insulin, the activity of LPL is increased leading to clearance of TG. Insulin 
also reduces VLDL secretion from the liver by affecting the assembly of VLDL particles 
in rodent hepatocytes [300]. We observed decreased TG levels only in VAD rats after the 
treatment of insulin, which indicates the role of VA in the regulation of TG metabolism. 
These results demonstrate the altered TG metabolism in VAD rats. The underlying 
mechanism deserves further investigation. 
Insulin is required to maintain the normal plasma level of leptin. Markedly 
reduced leptin levels had been observed in rats with insulin-deficient diabetes and 
treatment of insulin restored its levels [301]. Our observation that insulin treatment 
induced leptin levels in VAD rats is consistent with this study. However, we did not 
observe increased leptin levels in VAS rats treated with insulin. This is probably 
attributed to that VAS rats had more WAT leading to more leptin production than VAD 
rats did. Theoretically, VAS rats tend to have higher basal leptin levels than that of VAD 
rats. The short-term treatment (3-4 hr) in the current experimental setting may not be 
sufficient to change the expression and secretion of leptin protein. Thus, the effects of 
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insulin treatment for 3-4 hr on leptin levels in VAS rats may not be as efficient as that in 
VAD rats. It seems that RA can increase leptin levels based on our observation that RA 
treatment alone induced leptin levels in both VAS and VAD diabetic rats. This may 
partially explain why insulin treatment restored leptin levels in VAD rats but not in VAS 
rats. Stored VA may also contribute to the elevation of leptin levels in diabetic rats. So a 
dramatic induction of leptin levels by insulin treatment cannot be easily observed in VAS 
rats. The leptin levels in VAD rats that had no stored VA are more sensitive to the insulin 
treatment.  
We have shown that VAS ZL rats had higher hepatic mRNA levels of Gck than 
VAD ZL rats did [244] and RA alone induces or synergizes with insulin to induce Gck 
expression in primary rat hepatocytes [240]. This can explain that RA treatment only 
induced Gck expression in VAD rats but not that in VAS rats since VAS rats had higher 
Gck mRNA levels than VAD rats. Therefore, the anticipated RA-induced Gck expression 
in VAS rats may be masked or desensitized by endogenous RA production. The mRNA 
levels of Gck in VAD rats were more sensitive to the treatment of RA due to the lack of 
VA storage for RA production. Insulin treatment induced the Gck expression in both 
VAS and VAD rats, and the induction was more dramatic in VAD rats, probably due to 
the low basal level in the control rats. Treatment of insulin + RA significantly increased 
the mRNA levels of Gck of both VAS and VAD rats, and the increase in VAD rats was 
even higher than those with insulin treatment. These observations are matching our 
previous results [244]. RA treatment alone or in combination with insulin induces Gck 
expression in VAD diabetic rats.  
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We have observed elevated Srebp-1c expression levels in VAS rats compared to 
that in VAD rats [244], and RA synergizes with insulin to induce Srebp-1c expression in 
primary rat hepatocytes [245]. We did not observed higher Srebp-1c mRNA levels in 
VAS rats treated with insulin in this study, which may due to the short term of insulin 
treatment. We have shown that the insulin-induced Srebp-1c expression only becomes 
significant after 6 hr in primary rat hepatocytes. The immono-blot results of PEPCK and 
GK were consistent with the real-time PCR results. They also demonstrate that VA status 
affects the expression of ACC and FAS, which deserves further investigation.  
In summary, VA status affects the responses of nutrients and hormones in rats 
with STZ-induced diabetes to RA and insulin treatments. This indicates that VA status 
contributes to the regulation of expression of hepatic genes for glucose and lipid 
metabolism. VAD diabetes rats seem more sensitive to the treatment of RA or insulin. 
Dynamic RA production alone or in combination with insulin induces the expression of 
Gck and other genes for glucose and fatty acid homeostasis in VAD diabetic rats. The 
roles of VA in the regulation of gene expression in other tissues of diabetic rats need to 
be studied to comprehensively understand how it contributes to the glucose and lipid 
metabolism. We will also investigate the effects of dynamic RA production on the action 
of insulin on hepatic gene expression. 
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Figure 4- 1 Body mass and body compositions of VAS and VAD rats.  
(A) Body mass of STZ-treated Zucker lean rats were recorded weekly. Results were 
represented means ± SEM of 16 independent experiments. * for comparing the control 
rats fed a VAS diet and rats fed a VAD diet; all P < 0.05. The ratios of (B) liver/BM and 
(C) WAT/BM were calculated and compared between VAS and VAD rats. Data were 
represented means ± SEM of 4 independent experiments. * for comparing the control 
VAS rats and VAD rats at the indicated groups; all P<0.05. 
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Table 4- 1 Tail tip whole blood glucose levels of VAS and VAD rats after fasting, 
after STZ injection, and after treatment of saline, RA, INS, or INS + RA. 
 
  
 C RA INS INS+RA 
After fasting 94 (±4) 96 (±2) 85 (±7) 66 (±9) 
After STZ 
injection 424 (±71) 415 (±17) 539 (±16) 437 (±53) VAS 
After 
treatment 518
a (±39) 547a (±40) 77b (±20) 178c (±49) 
After fasting 81 (±5) 78 (±3) 74 (±4) 69 (±4) 
After STZ 
injection 403 (±15) 491 (±45) 490 (±29) 467 (±25) VAD 
After 
treatment 489
d (±65) 494d (±46) 116e (±39) 122e (±37) 
 
Tail tip whole blood glucose levels of STZ-treated Zucker lean rats were measured after 
48-hour fasting, 24 hr after STZ injection, and 3-4 hr after treatment of saline, RA, INS, 
or INS + RA. Results were represented means ± SEM of 4 independent experiments. 
a>c>b, d>e, P<0.05.  
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Figure 4- 2 Plasma levels of (A) Glucose, (B) TG, (C) Ketone, (D) Insulin, (E) Leptin, 
and (F) Glucagon of VAS and VAD rats after the reagent treatment.  
Accumulated venous plasma samples of STZ-treated Zucker lean rats were collected 3-4 
hr after the treatment of saline, RA, INS, or INS + RA. Glucose, TG, ketone, insulin, 
leptin, and glucagon levels were measured using the available commercial kits. Results 
were represented means ± SEM of 4 independent experiments. * for comparing the 
control VAS rats and VAD rats at the indicated groups; a>b, c>d, e>f, g>h, i>j, k<l, m<n, 
o<p, q>r, s>t, all P<0.05. 
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Figure 4- 3 Comparison of mRNA levels of (A) Cyp26a1, (B) Gck, (C) Pck1, and (D) 
Srebp-1c of VAS and VAD rats in response to the reagent treatment.  
Liver tissue samples were collected 3-4 hr after the reagent treatment. Total RNAs were 
extracted and subjected to real-time PCR analysis. Results were presented as means ± 
SEM of the -∆CT (the CT of 36B4 - the CT of indicated transcript) from 4 independent 
experiments. a<b, e<c<d<f, g<h, i<j<k<l, m>n, o>p, q<r, s<u<t, P<0.05. 
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Figure 4- 4 Comparison of the expression of CYP26A1 of STZ-treated Zucker lean 
(A) VAS rats and (B) VAD rats.  
Proteins (50 µg/lane) in whole cell lysates were isolated and subjected to immono-blot 
analysis.  
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Figure 4- 5 Comparison of the expression levels of protein of STZ-treated Zucker 
lean (A) VAS rats and (B) VAD rats in response to the treatment of saline, RA, INS, 
or INS + RA.  
Proteins (50 µg/lane) in whole cell lysates were isolated and subjected to immono-blot 
analysis. The ImageJ Software was used to determine the density of a protein band. 
Results were presented as means ± SEM from 3 independent experiments. a>b, c<d, 
a’<b’, d’<c’<e’, f’>g’, h’<i’<j’, all P<0.05. 
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Chapter Five 
General Discussion and Future Directions 
1. Roles of dynamic VA catabolism in the regulation of hepatic glucose and lipid 
gene expression 
1.1. The change of VA metabolism in obesity 
Given essential roles of VA in a variety of physiological functions, we set up 
experiments to determine the effect of VA metabolism in the regulation of hepatic 
glucose and lipid metabolism. Experimental data presented through this dissertation 
indicate that rapid and dynamic metabolism of VA seems to contribute significantly to 
the expression of genes involved in hepatic glucose and fatty acid metabolism in rats. 
This contribution also includes the modulation of the insulin’s action on gene expression. 
The intracellular VA in the liver comes from two sources: stored VA in hepatic 
stellate cells, and VA in the diet. VA is stored in stellate cells in the form of retinyl esters 
and is released as retinol as needed for use. VAS rats, with adequate stores of VA in the 
liver, can maintain constant plasma VA level when the diet is not sufficient. VAD rats 
that show early signs of VA deficiency have depleted hepatic VA stores and they are 
dependent on the dynamic VA supply from the diet. In this study, I compared the gene 
expression of VAS and VAD rats in response to different physiological conditions, the 
fasting and refeeding cycle and the Streptozotocin (STZ)-induced diabetes, to investigate 
the effects of VA status and dynamic VA catabolism on expression of hepatic genes for 
glucose and lipid metabolism. 
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We first compared the expression levels of hepatic genes for the generation of RA 
in the liver of insulin-sensitive ZL and -resistant ZF rats. ZF rats develop obesity due to 
the mutation of leptin receptor [249], which is associated with profound changes of 
hepatic gene expression. The comparison allows us to determine whether any of these 
changes can be attributed to the changes of catabolism of VA in the liver of ZF rats. 
Based on our observations demonstrated in Chapter 2, the expression levels of both 
Raldh1 mRNA and RALDH1 protein are higher in the liver of ZF than that of ZL rats. 
RALDH1 is the primary enzyme that converts retinal to retinoic acid (RA). We believe 
that the elevated expression of retinaldehyde dehydrogenase 1 (RALDH1) in the liver of 
Zucker fatty (ZF) rats contributes to increased lipogenesis through the induction of sterol 
regulatory element binding protein 1c (Srebp-1c). The hyperphagia of ZF rats can lead to 
the excessive intake of dietary VA and development of hyperinsulinemia. Excessive 
intake of dietary VA and elevated protein level of RALDH1 of ZF rats may trigger an 
increase in RA production that synergizes with insulin to induce Srebp-1c expression. 
The elevation of the mature SREBP-1c protein also induces the expression of Raldh1 
[65], which leads to more RA production, and further enhances the expression of Srebp-
1c and its downstream lipogenic genes. This creates a feed-forward mechanism by which 
the Srebp-1c expression is maintained at a higher level in the liver of ZF rats than that of 
Zucker lean (ZL) rats [280].  
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1.2. Roles of the VA status in the control of plasma glucose level and hepatic 
glucose homeostasis 
Glucose and lipid homeostasis is achieved in part by the regulation of the 
expression of hepatic genes involved in the process. Given the roles of VA in the 
regulation of the hepatic gene expression, it is anticipated that plasma glucose and lipid 
levels respond to VA status. This is what we have observed and presented in Chapters 3 
and 4.  
In ZL rats, we observed lower levels of plasma glucose, triacylglycerol (TG), 
insulin, leptin, and epididymal white adipose tissue (WAT) to body mass (BM) ratio of 
VA deficient (VAD) rats than that of VA sufficient (VAS) controls, which is consistent 
with the results in our previous studies [244].  We also observed reduced mRNA levels of 
Gck and Srebp-1c; and elevated Igfbp1 mRNA levels in the liver of VAD ZL rats in 
comparison to that of VAS rats, matching our previous observations [244].  
Glucose is the major source of energy for our body, and it is phosphorylated by 
hexokinases to generate glucose 6-phosphate for the use in cells. Hexokinase D, 
glucokinase (GK), is essential for glycolysis in the liver and pancreatic β-cells for the 
regulation of glucose homeostasis in the body. The Gck mRNA is induced by insulin and 
suppressed by glucagon in rat liver [302, 303], and the fasting and refeeding cycle 
changes the hepatic Gck expression [304]. We have shown that RA alone or synergizes 
with insulin to induce Gck expression in primary rat hepatocytes [240]. In this study, 
lower levels of hepatic Gck mRNA were observed in VAD rats as compared to that in 
VAS rats, demonstrating the involvement of VA in the regulation of Gck expression in 
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the liver. The VAD-refed-VAS rats had significantly higher hepatic expression levels of 
Gck mRNA than that of VAD-refed-VAD rats, which indicates that dynamic RA 
production contributes to the control of hepatic Gck expression.  
In STZ-induced diabetic rats, the hepatic Gck expression levels in VAD rats were 
more sensitive to the treatment of exogenous RA or insulin. This is probably due to the 
fact that VAD rats had comparatively lower basal levels of Gck mRNA than VAS rats so 
the induction of Gck expression by the treatment of RA or insulin in VAD rats was more 
dramatic than that in VAS rats. It seems that RA synergizes with insulin to induce the 
hepatic Gck expression in insulin-dependent diabetic rats. Thus, dynamic VA catabolism 
affects the hepatic Gck expression levels in STZ-induced diabetic rats. This might be a 
potential target for treatment of diabetes and deserves further investigation. 
Gluconeogenesis plays an essential role to maintain plasma glucose homeostasis 
during fasting. The cytosolic form of phosphoenolpuryvate carboxykinase (PEPCK-C) is 
the first rate-limiting enzyme of gluconeogenesis that converts oxaloacetate into 
phosphoenolpruvate in the presence of GTP. In the liver, insulin suppresses Pck1 
expression while glucagon induces its expression [305] so the liver can produces glucose 
in the fasting state. In our previous studies, we demonstrated that RA induced Pck1 
expression and attenuated insulin-mediated suppression of its expression in primary rat 
hepatocytes [243]. We did not observe any difference between the Pck1 mRNA levels of 
VAD rats and that of VAS rats, indicating that additional factors may contribute to the 
regulation of Pck1 mRNA. It is interesting to note that VAD-refed-VAD rats had higher 
expression levels of hepatic Pck1 mRNA than VAD-refed-VAS rats did. This is probably 
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due to the relatively lower levels of insulin in VAD-refed-VAD rats so the suppression of 
Pck1 expression by insulin is not as strong as that in VAD-refed-VAS rats. On the other 
hand, the consumed dietary VA or dynamic RA production in this case may not be 
sufficient to affect the insulin-mediated suppression of Pck1.  
In STZ-induced diabetic rats, the hepatic Pck1 mRNA levels were decreased upon 
the treatment of insulin or insulin + RA in both VAS and VAD rats. It is interesting to 
note that the reductions of hepatic Pck1 mRNA expression upon insulin treatment in 
VAD rats were more dramatic than that in VAS rats. This phenomenon may be attributed 
to that the catabolism of the stored VA attenuates the insulin-mediated suppression of 
Pck1 expression in STZ-induced VAS diabetic rats. It seems that VA status does not 
affect the Pck1 expression (Figure 4-3C). In addition, exogenous RA injection did not 
induce the Pck1 mRNA acutely.  
The hypoglycemia in VAD rats may be attributed to the reduced supply of 
glucose from glycogenolysis in the liver due to the depletion of hepatic glycogen content. 
It may also result from increased utilization of glucose as energy because of the reduced 
availability of fatty acids (FAs) from lipolysis. The VAD rats have depletion of their 
white adipose tissues. In addition, the VAD rats have reduction of food intake. These 
cause that the VAD animals have less resources available for gluconeogenesis, anabolism 
and energy production. Given glucose can be used by all cells in the body, it becomes an 
available energy source. Therefore, its plasma level drops in the VAD status. The 
hypoglycemia probably also contributes to the hypoinsulinemia in the VAD rats.  
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1.3. Roles of the VA status in the control of plasma TG level and hepatic fatty 
acid metabolism 
Fatty acid (FA) and TG homeostasis is regulated by the liver and adipose tissues 
in response to dietary and stored energy [306]. In the postprandial stage, the dietary and 
de novo synthetic FAs are stored in adipose tissues as TG [307]. Lipoprotein lipase (LPL) 
hydrolyzes TG in chylomicrons and very low-density lipoprotein (VLDL) into free FAs 
(FFAs), monoglycerides, and diglycerides to enter adipose tissues [307]. During fasting 
or starvation, FFAs are released from adipose tissues via lipolysis and used as energy by 
the liver, heart, and skeletal muscle. Insulin induces lipogenesis and inhibits lipolysis 
[291]. The action mediated by insulin is through the stimulation of the expression of 
lipogenic genes, a process mainly controlled by SREBP-1c [227].  
We have reported that RA alone or synergizes with insulin to induce Srebp-1c 
expression in primary rat hepatocytes [245]. In this study, we observed reduced hepatic 
expression levels of Srebp-1c in VAD rats as compared to VAS rats. Thus, VA status 
affects the expression of Srebp-1c mRNA. The reduction of expression of hepatic 
lipogenic genes, such as Srebp-1c, may be responsible for the lower plasma TG levels 
and hepatic FA biosynthesis of VAD rats, which could also explain the reduced 
WAT/BM ratio of VAD rats. Another explanation is that RA may reduce the LPL 
activity in adipose tissue and skeletal muscle to decrease the clearance of TG leading to 
higher TG levels in VAS rats.  
The VAD-refed-VAS rats had markedly higher hepatic expression levels of 
Srebp-1c than VAD-refed-VAD rats did. The hepatic mRNA levels of FA synthase gene 
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(Fas) in VAD-refed-VAS were also higher than that in VAD-refed-VAD rats. This 
demonstrates that the dynamic RA production contributes to the insulin-mediated 
regulation of Srebp-1c expression and the expression of its downstream gene Fas. In 
STZ-induced diabetic rats, treatment of insulin or insulin + RA induced the hepatic 
Srebp-1c expression levels in both VAS and VAD rats, but the inductions in VAD rats 
were more significant than that in VAS rats. This is probably due to the lower basal level 
of Srebp-1c in the liver of STZ-induced VAD rats. RA synergizes with insulin to induce 
Srebp-1c expression in STZ-induced diabetic rats. Thus, both stored VA and dynamic 
VA catabolism contribute to the insulin-mediated Srebp-1c expression.  
1.4. Possible roles of VA catabolism in the development of insulin resistance in 
the liver 
We have demonstrated in this dissertation that VA status and dynamic VA 
catabolism, with the combination of insulin, regulate expression of hepatic genes for 
glucose and lipid metabolism in different physiological conditions, such as the cycle of 
fasting and refeeding and STZ-induced diabetes. Dynamic RA production is primarily 
controlled by enzymes responsible for the synthesis of retinal and then RA. In this 
process, the expression of RALDH1 probably is critical as it converts retinal to RA 
irreversibly.  
A common feature of obesity and type 2 diabetes mellitus (T2DM) is insulin 
resistance, which a given amount of insulin produces less than normal physiological 
responses. Insulin resistance is always associated with profound changes of expression 
levels of genes for the hepatic glucose and fatty acid metabolism. Generally, the liver of 
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an insulin-resistant animal loses the response to insulin regarding insulin-regulated 
glucose metabolism, but still retains the elevated lipogenesis. This results in a vicious 
cycle, which may accelerate the development of T2DM. ZF rats are obese and insulin 
resistant. We think that VA status and RA product play a role in the development of the 
hepatic insulin resistance in them. The increased lipogenesis in ZF rats can be explained 
by the feed-forward mechanism we mentioned above. As shown in Figure 5-1, dietary or 
endogenous VA enters into an intracellular pool, which is used for the RA product 
through a two-step oxidation process. In normal physiological condition, RA produced 
via this process is controlled by the expression levels and activities of RALDHs. The 
dynamic amount of RA contributes to the regulation of the expression of insulin-
regulated genes in hepatocytes.  In obese or insulin resistant animals, this homeostasis is 
disrupted. In the presence of excessive intake or catabolism of VA results in the over-
production of RA, which alters the expression of RA and insulin-regulated genes for 
glucose and lipid metabolism in the liver. This may lead to the development of hepatic 
insulin resistance at the gene expression level.  
 
2. Roles of VA in the regulation of energy balance of whole body 
Given the strong effects of VA status and its catabolism in the control of the 
hepatic glucose and lipid homeostasis, it is reasonable to hypothesize that whole body 
energy balance can be affected by VA status. Using the CLAMS system, we monitored 
the energy expenditure of rats along with their body mass change in the course of 
development of VA deficiency.  
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We have observed that VA status contributes to the energy usage and balance of 
the whole body. Respiratory exchange ratio (RER) is a parameter that indicates the 
relative production of CO2 derived from carbohydrate and fatty acids in the oxidation 
process for the production of energy. RER reflects the respiratory quotient (RQ), an 
indicator of which fuel is being metabolized to supply the body with energy.  The data 
presented in Chapter 3 demonstrate that RER of rats fed the VAS diet is higher than that 
of rats fed the VAD diet starting from week 4 after the ZL rats were fed their perspective 
diet. The data show that the ZL rats fed the VAS diet are using carbohydrate as the 
primary energy source and synthesized FAs as evidenced by their elevated RER values 
towards 1.0 after week 4. This indicates that ZL rats fed the VAS diet were in the 
anabolic state at week 4, an energy demanding process during which gluconeogenesis, 
glycogenesis, and lipogenesis occur. On the contrary, the RER values of ZL rats fed the 
VAD diet remained at about 0.85, which was lower than that of VAS rats after week 4. 
This suggests that ZL rats fed the VAD diet used a mixture of carbohydrate and FAs as 
the energy source and they were in the catabolic state, an oxidative process during which 
glycolysis, glycogenolysis, and β-oxidation occur. The RER data suggest that VA status 
plays a role in the regulation of the fuel metabolism in rats. VA is required to maintain 
the anabolic state in rats.  
VA probably affects RER through multiple mechanisms. First, VA contributes to 
the hepatic glucose usage and fatty acid biosynthesis. We have shown that VA synergizes 
with insulin to induce the hepatic expression of Gck and Srebp-1c. This induction clearly 
promotes the conversion of glucose to fatty acids, indicating an anabolic process. Second, 
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VA is needed for the storage of glucose into glycogen. It has been shown that 
glycogenesis is impaired in VAD rats [244, 308], indicating the need of VA for 
glycogenesis. Third, VA is needed to maintain the presence of adipose tissue. We and 
others have shown that VA deficiency causes rats to lose their body fat, and reduction of 
plasma TG level. Forth, VA is needed for the proper development of pancreas, and 
secretion of insulin and glucagon in rats [157]. It has been shown that glucose-stimulated 
insulin secretion (GSIS) of VAD rats from pancreatic β-cells was impaired [157], which 
may contribute to the hypoinsulinemia in VAD rats. Insulin as the anabolic hormone is 
needed for the induction fatty acid biosynthesis, and accumulation of TG in adipose 
tissue. Without insulin action, the body will tend to be in a catabolic state. Additional 
experiments are needed to test the roles of any one or all of these pathways in the VA’s 
effects on RER. 
Other than the RER, we also measured the accumulated heat production in rats 
fed the VAD or VAS diet. Our data demonstrate that the accumulated heat production of 
rats fed the VAS diet for 4 weeks was higher than that fed the VAD diet. This result is 
probably due to the larger body size of VAS rats that produces more heat. After we 
normalized the heat production to BM, the adjusted heat production in rats fed the VAS 
diet was no longer different from that in rats fed the VAD diet. Since VAD rats had lower 
WAT/BM ratio than VAS rats did, it suggests that the VAD rats may have relatively 
higher lean BM to total BM ratio. Theoretically, muscle produces more heat than fat 
does. To maintain the same adjusted heat production rate, the heat production rate per 
unit of muscle mass of VAD rats might be lower than that of VAS rats. This phenomenon 
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suggests that VA status may also affect the muscle metabolism. Indeed, it has been 
shown that RA can induce the expression levels of uncoupling proteins in the culture 
skeletal muscle cell lines [309]. The elevated expression levels of uncoupling protein 
(UCP) will increase the dissipation of energy in the form of heat. This phenomenon 
seems to support our conclusion, which VA deficiency might reduce the heat production 
in the skeletal muscle. Further studies are needed to investigate the role of VA status in 
muscle metabolism and heat production.  
 
3. Future perspective 
This dissertation demonstrates that VA status and its metabolism play a critical 
role in the fuel homeostasis and energy utilization. It also raises more questions regarding 
the underlying molecular mechanisms of the observations. We believe that the following 
research areas deserve to be investigated further. 
3.1. The contribution of RALDH1 in the development of hepatic insulin 
resistance at gene expression level 
We hypothesize that SREBP-1c regulates the expression of Raldh1 mRNA and 
dynamic RA production mediated by RALDH1 affects the action of insulin. To further 
study whether alteration of RALDH1 expression will affect the expression of insulin-
mediated genes, and whether SREBP-1c regulates its expression in the hepatocytes or the 
liver of rats, we can first knockdown the expression of Raldh1 in rat hepatocytes and 
analyze the insulin-regulated gene expression. In addition, we can overexpress and 
knockdown the expression of Srebp-1c in rat hepatocytes and analyze the expression 
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levels of Raldh1 and Cyp26a1, an indicator of RA production. In such a way, we will be 
able to demonstrate the existence of a feed-forward cycle between RALDH1 and SREBP-
1c, and in turn to understand the molecular mechanism of the hepatic insulin resistance at 
gene expression level.  
3.2. The role of VA in normal and disease conditions 
We demonstrate that VA is essential for maintaining the normal action of insulin 
in the liver of rats, and VA status may affect the insulin-mediated gene expression in the 
liver of ZL rats. An open question is whether VA is essential for the development of 
insulin resistance and obesity in high-fat diet (HFD)-induced obesity. As a fat-soluble 
vitamin, VA intake can be elevated with the intake of HFD. Therefore, we can set up 
experiment to determine the role of VA in the development of HFD-induced obesity in 
rats. ZL or other stain of rats will be fed either a high-fat diet (HFD) with sufficient 
amount of VA or a HFD without VA diet for 8 weeks after they are weaned. The growth 
and development of obesity will be analyzed during this course. Tissues and plasma 
samples will be collected at the end of the experiment. They will be compared between 
the VAD and VAS groups to determine the role of VA in the HFD-induced obesity and 
insulin resistance. 
3.3. The mechanism by which VA affects the whole body energy usage. 
RA has been reported to induce the expression of thermogenic UCP-1 in primary 
rat brown adipocyte [310] and stimulate UCP-3 in the muscle of mice [309]. Thus, we 
believe that VA status affects the whole body energy expenditure by the modulation of 
expression the expression of genes involved in thermogenesis. Brown adipose tissue 
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(BAT) and muscle from VAD and VAS rats will be collected and subjected to analysis. 
The expression levels of UCP-1 will be analyzed in the BAT of VAS and VAD ZL rats. 
The expression levels of enzymes in glucose and fatty acid expression, and 
thermogenesis such as UCP-3 in the muscle of VAS and VAD ZL rats will be compared. 
These data will be combined with the RER and the accumulated heat production data to 
disclose the role of VA in whole body energy usage and production.   
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Figure 5- 1 The effects of RA on the insulin-regulated Srebp-1c and Pck1 expression 
levels, the protein levels of SREBP-1c, the expression levels of Raldh1 and Fas, and 
the fatty acid synthesis and gluconeogenesis in insulin-sensitive (a) and insulin-
resistant (b) hepatocytes.  
(A) In insulin-sensitive hepatocytes, RA derived from retinal coordinates with insulin to 
regulate the expression of Srebp-1c and Pck1. The SREBP-1c protein is processed to 
mature form, which enters into the nucleus and induces the mRNA levels 
of Raldh1 and Fas, which are, respectively, transcribed into RALDH1 and FAS. 
RALDH1 catalyzes the conversion of retinal to RA. FAS catalyzes the synthesis of 
palmitate, which is esterified into TGs or elongated to longer FAs. The Pck1 mRNA is 
used to translate into PEPCK-C protein, which contributes to glucogenogenesis. (B) In 
the insulin-resistant hepatocytes, the elevation of Raldh1expression due to leptin 
deficiency or induction of SREBP-1c by high-cholesterol feeding induces the production 
of RA. The elevated RA levels will stimulate the transcription of Srebp-1c and Pck1. This 
leads to more production of SREBP-1c, and its mature form, in the presence of higher 
insulin levels in the insulin-resistant state. The induction of SREBP-1c further enhances 
the transcription of Raldh1 and Fas, and their corresponding proteins for the production 
of more RAs and FAs, respectively. The RA production and SREBP-1c expression form 
a feed-forward cycle, which causes more TG and RA production in the insulin-resistant 
liver. At the same time, more of the PEPCK-C protein is generated due to the 
elevated Pck1transcription by RA stimulation, which is not responsive to insulin 
inhibition. This leads to elevated gluconeogenesis in the insulin-resistant liver. 
Eventually, the phenotypes appear as if insulin no longer suppresses gluconeogenesis 
while it still stimulates FA synthesis in the insulin-resistant state. 
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(A)  Insulin-sensitive hepatocytes. 
 
 
(B) Insulin-resistant hepatocytes. 
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